{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:45:29Z","timestamp":1776127529088,"version":"3.50.1"},"publisher-location":"New York, NY","reference-count":266,"publisher":"Springer New York","isbn-type":[{"value":"9781493995035","type":"print"},{"value":"9781493995042","type":"electronic"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1007\/978-1-4939-9504-2_11","type":"book-chapter","created":{"date-parts":[[2019,5,27]],"date-time":"2019-05-27T10:02:44Z","timestamp":1558951364000},"page":"235-271","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Design of Oxytocin Analogs"],"prefix":"10.1007","author":[{"given":"Kazimierz","family":"Wi\u015bniewski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,28]]},"reference":[{"issue":"2","key":"11_CR1","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1152\/physrev.2001.81.2.629","volume":"81","author":"G Gimpl","year":"2001","unstructured":"Gimpl G, Fahrenholz F (2001) The oxytocin receptor system: structure, function, and regulation. Physiol Rev 81(2):629\u2013683","journal-title":"Physiol Rev"},{"issue":"5","key":"11_CR2","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S1043-2760(03)00080-8","volume":"14","author":"HH Zingg","year":"2003","unstructured":"Zingg HH, Laporte SA (2003) The oxytocin receptor. Trends Endocrinol Metab 14(5):222\u2013227","journal-title":"Trends Endocrinol Metab"},{"issue":"2","key":"11_CR3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1677\/jme.0.0300109","volume":"30","author":"T Kimura","year":"2003","unstructured":"Kimura T, Saji F, Nishimori K et al (2003) Molecular regulation of the oxytocin receptor in peripheral organs. J Mol Endocrinol 30(2):109\u2013115","journal-title":"J Mol Endocrinol"},{"key":"11_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2015.00335","volume":"9","author":"DA Baribeau","year":"2015","unstructured":"Baribeau DA, Anagnostou E (2015) Oxytocin and vasopressin: linking pituitary neuropeptides and their receptors to social neurocircuits. Front Neurosci 9:335. https:\/\/doi.org\/10.3389\/fnins.2015.00335","journal-title":"Front Neurosci"},{"issue":"2","key":"11_CR5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.physbeh.2010.05.004","volume":"101","author":"JG Veening","year":"2010","unstructured":"Veening JG, de Jong T, Barendregt HP (2010) Oxytocin-messages via the cerebrospinal fluid: behavioral effects; a review. Physiol Behav 101(2):193\u2013210. https:\/\/doi.org\/10.1016\/j.physbeh.2010.05.004","journal-title":"Physiol Behav"},{"issue":"1\u20132","key":"11_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.regpep.2006.03.008","volume":"135","author":"B Ohlsson","year":"2006","unstructured":"Ohlsson B, Truedsson M, Djerf P et al (2006) Oxytocin is expressed throughout the human gastrointestinal tract. Regul Pept 135(1\u20132):7\u201311. https:\/\/doi.org\/10.1016\/j.regpep.2006.03.008","journal-title":"Regul Pept"},{"issue":"21","key":"11_CR7","doi-asserted-by":"publisher","first-page":"11704","DOI":"10.1073\/pnas.94.21.11704","volume":"94","author":"J Gutkowska","year":"1997","unstructured":"Gutkowska J, Jankowski M, Lambert C et al (1997) Oxytocin releases atrial natriuretic peptide by combining with oxytocin receptors in the heart. Proc Natl Acad Sci U S A 94(21):11704\u201311709","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"11_CR8","doi-asserted-by":"publisher","first-page":"R970","DOI":"10.1152\/ajpregu.00040.2014","volume":"307","author":"G Colaianni","year":"2014","unstructured":"Colaianni G, Sun L, Zaidi M et al (2014) Oxytocin and bone. Am J Physiol Regul Integr Comp Physiol 307(8):R970\u2013R977. https:\/\/doi.org\/10.1152\/ajpregu.00040.2014","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"2","key":"11_CR9","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1097\/00003081-199506000-00006","volume":"38","author":"JM Shyken","year":"1995","unstructured":"Shyken JM, Petrie RH (1995) Oxytocin to induce labor. Clin Obstet Gynecol 38(2):232\u2013245","journal-title":"Clin Obstet Gynecol"},{"issue":"12","key":"11_CR10","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1038\/nrendo.2017.115","volume":"13","author":"EA Lawson","year":"2017","unstructured":"Lawson EA (2017) The effects of oxytocin on eating behaviour and metabolism in humans. Nat Rev Endocrinol 13(12):700\u2013709. https:\/\/doi.org\/10.1038\/nrendo.2017.115","journal-title":"Nat Rev Endocrinol"},{"key":"11_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.physbeh.2017.03.007","volume":"176","author":"MS Spetter","year":"2017","unstructured":"Spetter MS, Hallschmid M (2017) Current findings on the role of oxytocin in the regulation of food intake. Physiol Behav 176:31\u201339. https:\/\/doi.org\/10.1016\/j.physbeh.2017.03.007","journal-title":"Physiol Behav"},{"issue":"5","key":"11_CR12","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.tem.2017.02.007","volume":"28","author":"G Leng","year":"2017","unstructured":"Leng G, Sabatier N (2017) Oxytocin\u2014the sweet hormone? Trends Endocrinol Metab 28(5):365\u2013376. https:\/\/doi.org\/10.1016\/j.tem.2017.02.007","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"11_CR13","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1073\/pnas.1523762113","volume":"113","author":"L Sun","year":"2016","unstructured":"Sun L, Tamma R, Yuen T et al (2016) Functions of vasopressin and oxytocin in bone mass regulation. Proc Natl Acad Sci U S A 113(1):164\u2013169. https:\/\/doi.org\/10.1073\/pnas.1523762113","journal-title":"Proc Natl Acad Sci U S A"},{"key":"11_CR14","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/bs.pmbts.2016.08.004","volume":"143","author":"T Yuen","year":"2016","unstructured":"Yuen T, Sun L, Liu P et al (2016) Beyond reproduction: pituitary hormone actions on bone. Prog Mol Biol Transl Sci 143:175\u2013185. https:\/\/doi.org\/10.1016\/bs.pmbts.2016.08.004","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"2","key":"11_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1515\/hmbci-2016-0045","volume":"28","author":"EZ Amri","year":"2016","unstructured":"Amri EZ, Pisani DF (2016) Control of bone and fat mass by oxytocin. Horm Mol Biol Clin Investig 28(2):95\u2013104. https:\/\/doi.org\/10.1515\/hmbci-2016-0045","journal-title":"Horm Mol Biol Clin Investig"},{"issue":"Pt B","key":"11_CR16","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.physbeh.2015.05.023","volume":"152","author":"JE Blevins","year":"2015","unstructured":"Blevins JE, Baskin DG (2015) Translational and therapeutic potential of oxytocin as an anti-obesity strategy: insights from rodents, nonhuman primates and humans. Physiol Behav 152(Pt B):438\u2013449. https:\/\/doi.org\/10.1016\/j.physbeh.2015.05.023","journal-title":"Physiol Behav"},{"issue":"5","key":"11_CR17","doi-asserted-by":"publisher","first-page":"R431","DOI":"10.1152\/ajpregu.00441.2014","volume":"308","author":"JE Blevins","year":"2015","unstructured":"Blevins JE, Graham JL, Morton GJ et al (2015) Chronic oxytocin administration inhibits food intake, increases energy expenditure, and produces weight loss in fructose-fed obese rhesus monkeys. Am J Physiol Regul Integr Comp Physiol 308(5):R431\u2013R438. https:\/\/doi.org\/10.1152\/ajpregu.00441.2014","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"4","key":"11_CR18","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/j.1365-2826.2011.02235.x","volume":"24","author":"J Gutkowska","year":"2012","unstructured":"Gutkowska J, Jankowski M (2012) Oxytocin revisited: its role in cardiovascular regulation. J Neuroendocrinol 24(4):599\u2013608. https:\/\/doi.org\/10.1111\/j.1365-2826.2011.02235.x","journal-title":"J Neuroendocrinol"},{"issue":"1","key":"11_CR19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12902-016-0110-1","volume":"16","author":"M Jankowski","year":"2016","unstructured":"Jankowski M, Broderick TL, Gutkowska J (2016) Oxytocin and cardioprotection in diabetes and obesity. BMC Endocr Disord 16(1):34. https:\/\/doi.org\/10.1186\/s12902-016-0110-1","journal-title":"BMC Endocr Disord"},{"key":"11_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.yhbeh.2016.11.012","volume":"91","author":"NV Motta-Mena","year":"2017","unstructured":"Motta-Mena NV, Puts DA (2017) Endocrinology of human female sexuality, mating, and reproductive behavior. Horm Behav 91:19\u201335. https:\/\/doi.org\/10.1016\/j.yhbeh.2016.11.012","journal-title":"Horm Behav"},{"issue":"1","key":"11_CR21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.psychres.2014.11.048","volume":"226","author":"JB Zik","year":"2015","unstructured":"Zik JB, Roberts DL (2015) The many faces of oxytocin: implications for psychiatry. Psychiatry Res 226(1):31\u201337. https:\/\/doi.org\/10.1016\/j.psychres.2014.11.048","journal-title":"Psychiatry Res"},{"key":"11_CR22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ejphar.2014.07.045","volume":"753","author":"JG Veening","year":"2015","unstructured":"Veening JG, de Jong TR, Waldinger MD et al (2015) The role of oxytocin in male and female reproductive behavior. Eur J Pharmacol 753:209\u2013228. https:\/\/doi.org\/10.1016\/j.ejphar.2014.07.045","journal-title":"Eur J Pharmacol"},{"key":"11_CR23","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.conb.2014.09.012","volume":"29","author":"R Stoop","year":"2014","unstructured":"Stoop R (2014) Neuromodulation by oxytocin and vasopressin in the central nervous system as a basis for their rapid behavioral effects. Curr Opin Neurobiol 29:187\u2013193. https:\/\/doi.org\/10.1016\/j.conb.2014.09.012","journal-title":"Curr Opin Neurobiol"},{"issue":"3","key":"11_CR24","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.biopsych.2015.06.004","volume":"79","author":"ID Neumann","year":"2015","unstructured":"Neumann ID, Slattery DA (2015) Oxytocin in general anxiety and social fear: a translational approach. Biol Psychiatry 79(3):213\u2013221. https:\/\/doi.org\/10.1016\/j.biopsych.2015.06.004","journal-title":"Biol Psychiatry"},{"key":"11_CR25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.neuint.2016.12.021","volume":"103","author":"Q Xin","year":"2017","unstructured":"Xin Q, Bai B, Liu W (2017) The analgesic effects of oxytocin in the peripheral and central nervous system. Neurochem Int 103:57\u201364. https:\/\/doi.org\/10.1016\/j.neuint.2016.12.021","journal-title":"Neurochem Int"},{"key":"11_CR26","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.neuroscience.2017.09.041","volume":"387","author":"S. Boll","year":"2018","unstructured":"Boll S, Almeida de Minas AC, Raftogianni A et al (2017) Oxytocin and pain perception: from animal models to human research. Neuroscience. https:\/\/doi.org\/10.1016\/j.neuroscience.2017.09.041","journal-title":"Neuroscience"},{"issue":"4","key":"11_CR27","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ajog.2010.03.007","volume":"203","author":"SQ Wei","year":"2010","unstructured":"Wei SQ, Luo ZC, Qi HP et al (2010) High-dose vs. low-dose oxytocin for labor augmentation: a systematic review. Am J Obstet Gynecol 203(4):296\u2013304. https:\/\/doi.org\/10.1016\/j.ajog.2010.03.007","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"11_CR28","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/jmwh.12610","volume":"62","author":"K Page","year":"2017","unstructured":"Page K, McCool WF, Guidera M (2017) Examination of the pharmacology of oxytocin and clinical guidelines for use in labor. J Midwifery Women\u2019s Health 62(4):425\u2013433. https:\/\/doi.org\/10.1111\/jmwh.12610","journal-title":"J Midwifery Women\u2019s Health"},{"issue":"11","key":"11_CR29","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1517\/14656566.2015.1060960","volume":"16","author":"DA Wing","year":"2015","unstructured":"Wing DA, Sheibani L (2015) Pharmacotherapy options for labor induction. Expert Opin Pharmacother 16(11):1657\u20131668. https:\/\/doi.org\/10.1517\/14656566.2015.1060960","journal-title":"Expert Opin Pharmacother"},{"issue":"11","key":"11_CR30","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1080\/17474086.2016.1245135","volume":"9","author":"L Sentilhes","year":"2016","unstructured":"Sentilhes L, Merlot B, Madar H et al (2016) Postpartum haemorrhage: prevention and treatment. Expert Rev Hematol 9(11):1043\u20131061. https:\/\/doi.org\/10.1080\/17474086.2016.1245135","journal-title":"Expert Rev Hematol"},{"issue":"6287","key":"11_CR31","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1136\/bmj.283.6287.340","volume":"283","author":"H Ruis","year":"1981","unstructured":"Ruis H, Rolland R, Doesburg W et al (1981) Oxytocin enhances onset of lactation among mothers delivering prematurely. Br Med J (Clin Res Ed) 283(6287):340\u2013342","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"3","key":"11_CR32","doi-asserted-by":"publisher","first-page":"F169","DOI":"10.1136\/adc.2005.081265","volume":"91","author":"MS Fewtrell","year":"2006","unstructured":"Fewtrell MS, Loh KL, Blake A et al (2006) Randomised, double blind trial of oxytocin nasal spray in mothers expressing breast milk for preterm infants. Arch Dis Child Fetal Neonatal Ed 91(3):F169\u2013F174. https:\/\/doi.org\/10.1136\/adc.2005.081265","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"7042","key":"11_CR33","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nature03701","volume":"435","author":"M Kosfeld","year":"2005","unstructured":"Kosfeld M, Heinrichs M, Zak PJ et al (2005) Oxytocin increases trust in humans. Nature 435(7042):673\u2013676. https:\/\/doi.org\/10.1038\/nature03701","journal-title":"Nature"},{"issue":"2","key":"11_CR34","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1586\/ern.10.199","volume":"11","author":"D Feifel","year":"2011","unstructured":"Feifel D (2011) Is oxytocin a promising treatment for schizophrenia? Expert Rev Neurother 11(2):157\u2013159. https:\/\/doi.org\/10.1586\/ern.10.199","journal-title":"Expert Rev Neurother"},{"issue":"3","key":"11_CR35","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.biopsych.2015.06.028","volume":"79","author":"AJ Guastella","year":"2016","unstructured":"Guastella AJ, Hickie IB (2016) Oxytocin treatment, circuitry, and autism: a critical review of the literature placing oxytocin into the autism context. Biol Psychiatry 79(3):234\u2013242. https:\/\/doi.org\/10.1016\/j.biopsych.2015.06.028","journal-title":"Biol Psychiatry"},{"issue":"2","key":"11_CR36","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40263-016-0313-z","volume":"30","author":"MR Lee","year":"2016","unstructured":"Lee MR, Rohn MC, Tanda G et al (2016) Targeting the oxytocin system to treat addictive disorders: rationale and progress to date. CNS Drugs 30(2):109\u2013123. https:\/\/doi.org\/10.1007\/s40263-016-0313-z","journal-title":"CNS Drugs"},{"issue":"14","key":"11_CR37","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1111\/bph.13757","volume":"175","author":"Panos Zanos","year":"2017","unstructured":"Zanos P, Georgiou P, Weber C et al (2017) Oxytocin and opioid addiction revisited: old drug, new applications. Br J Pharmacol. https:\/\/doi.org\/10.1111\/bph.13757","journal-title":"British Journal of Pharmacology"},{"issue":"12","key":"11_CR38","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.tins.2017.10.003","volume":"40","author":"MT Bowen","year":"2017","unstructured":"Bowen MT, Neumann ID (2017) Rebalancing the addicted brain: oxytocin interference with the neural substrates of addiction. Trends Neurosci 40(12):691\u2013708. https:\/\/doi.org\/10.1016\/j.tins.2017.10.003","journal-title":"Trends Neurosci"},{"key":"11_CR39","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.neubiorev.2015.04.013","volume":"55","author":"LM Tracy","year":"2015","unstructured":"Tracy LM, Georgiou-Karistianis N, Gibson SJ et al (2015) Oxytocin and the modulation of pain experience: implications for chronic pain management. Neurosci Biobehav Rev 55:53\u201367. https:\/\/doi.org\/10.1016\/j.neubiorev.2015.04.013","journal-title":"Neurosci Biobehav Rev"},{"issue":"7","key":"11_CR40","doi-asserted-by":"publisher","first-page":"906","DOI":"10.2174\/1381612820666141027111843","volume":"21","author":"BR Goodin","year":"2015","unstructured":"Goodin BR, Ness TJ, Robbins MT (2015) Oxytocin\u2014a multifunctional analgesic for chronic deep tissue pain. Curr Pharm Des 21(7):906\u2013913","journal-title":"Curr Pharm Des"},{"key":"11_CR41","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/1471-244X-14-92","volume":"14","author":"JL Frijling","year":"2014","unstructured":"Frijling JL, van Zuiden M, Koch SB et al (2014) Efficacy of oxytocin administration early after psychotrauma in preventing the development of PTSD: study protocol of a randomized controlled trial. BMC Psychiatry 14:92. https:\/\/doi.org\/10.1186\/1471-244X-14-92","journal-title":"BMC Psychiatry"},{"issue":"3","key":"11_CR42","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s40263-016-0315-x","volume":"30","author":"PD Shilling","year":"2016","unstructured":"Shilling PD, Feifel D (2016) Potential of oxytocin in the treatment of schizophrenia. CNS Drugs 30(3):193\u2013208. https:\/\/doi.org\/10.1007\/s40263-016-0315-x","journal-title":"CNS Drugs"},{"issue":"3","key":"11_CR43","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.biopsych.2015.07.025","volume":"79","author":"D Feifel","year":"2016","unstructured":"Feifel D, Shilling PD, MacDonald K (2016) A review of oxytocin's effects on the positive, negative, and cognitive domains of schizophrenia. Biol Psychiatry 79(3):222\u2013233. https:\/\/doi.org\/10.1016\/j.biopsych.2015.07.025","journal-title":"Biol Psychiatry"},{"issue":"9","key":"11_CR44","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1002\/ajmg.a.36653","volume":"164A","author":"SL Einfeld","year":"2014","unstructured":"Einfeld SL, Smith E, McGregor IS et al (2014) A double-blind randomized controlled trial of oxytocin nasal spray in Prader-Willi syndrome. Am J Med Genet A 164A(9):2232\u20132239. https:\/\/doi.org\/10.1002\/ajmg.a.36653","journal-title":"Am J Med Genet A"},{"key":"11_CR45","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.brainres.2013.11.009","volume":"1580","author":"S Kim","year":"2014","unstructured":"Kim S, Soeken TA, Cromer SJ et al (2014) Oxytocin and postpartum depression: delivering on what's known and what's not. Brain Res 1580:219\u2013232. https:\/\/doi.org\/10.1016\/j.brainres.2013.11.009","journal-title":"Brain Res"},{"key":"11_CR46","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.yhbeh.2015.08.008","volume":"77","author":"S Brummelte","year":"2016","unstructured":"Brummelte S, Galea LA (2016) Postpartum depression: etiology, treatment and consequences for maternal care. Horm Behav 77:153\u2013166. https:\/\/doi.org\/10.1016\/j.yhbeh.2015.08.008","journal-title":"Horm Behav"},{"issue":"1","key":"11_CR47","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1177\/2045125316672574","volume":"7","author":"RR Tampi","year":"2017","unstructured":"Tampi RR, Maksimowski M, Ahmed M et al (2017) Oxytocin for frontotemporal dementia: a systematic review. Ther Adv Psychopharmacol 7(1):48\u201353. https:\/\/doi.org\/10.1177\/2045125316672574","journal-title":"Ther Adv Psychopharmacol"},{"issue":"1\u20132","key":"11_CR48","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.psychres.2014.07.082","volume":"220","author":"LR Horta de Macedo","year":"2014","unstructured":"Horta de Macedo LR, Zuardi AW, Machado-de-Sousa JP et al (2014) Oxytocin does not improve performance of patients with schizophrenia and healthy volunteers in a facial emotion matching task. Psychiatry Res 220(1\u20132):125\u2013128. https:\/\/doi.org\/10.1016\/j.psychres.2014.07.082","journal-title":"Psychiatry Res"},{"issue":"4","key":"11_CR49","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/jcpp.12305","volume":"56","author":"AJ Guastella","year":"2014","unstructured":"Guastella AJ, Gray KM, Rinehart NJ et al (2014) The effects of a course of intranasal oxytocin on social behaviors in youth diagnosed with autism spectrum disorders: a randomized controlled trial. J Child Psychol Psychiatry 56(4):444\u2013452. https:\/\/doi.org\/10.1111\/jcpp.12305","journal-title":"J Child Psychol Psychiatry"},{"issue":"2","key":"11_CR50","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0021-9258(18)49238-1","volume":"205","author":"V Vigneaud du","year":"1953","unstructured":"du Vigneaud V, Ressler C, Trippett S (1953) The sequence of amino acids in oxytocin, with a proposal for the structure of oxytocin. J Biol Chem 205(2):949\u2013957","journal-title":"J Biol Chem"},{"key":"11_CR51","doi-asserted-by":"publisher","first-page":"4879","DOI":"10.1021\/ja01115a553","volume":"75","author":"V Vigneaud du","year":"1953","unstructured":"du Vigneaud V, Ressler C, Swan JM et al (1953) The synthesis of an octapeptide amide with the hormonal activity of oxytocin. J Am Chem Soc 75:4879\u20134880","journal-title":"J Am Chem Soc"},{"key":"11_CR52","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0079-6123(08)00417-2","volume":"170","author":"G Gimpl","year":"2008","unstructured":"Gimpl G, Reitz J, Brauer S et al (2008) Oxytocin receptors: ligand binding, signalling and cholesterol dependence. Prog Brain Res 170:193\u2013204. https:\/\/doi.org\/10.1016\/S0079-6123(08)00417-2","journal-title":"Prog Brain Res"},{"issue":"Pt 2","key":"11_CR53","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1042\/bj3540465","volume":"354","author":"SR Hawtin","year":"2001","unstructured":"Hawtin SR, Howard HC, Wheatley M (2001) Identification of an extracellular segment of the oxytocin receptor providing agonist-specific binding epitopes. Biochem J 354(Pt 2):465\u2013472","journal-title":"Biochem J"},{"issue":"2","key":"11_CR54","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/0014-2999(70)90306-7","volume":"9","author":"I Polacek","year":"1970","unstructured":"Polacek I, Krejci I, Nesvadba H et al (1970) Action of (1,6-di-alanine)-oxytocin and (1,6-di-serine)-oxytocin on the rat uterus and mammary gland in vitro. Eur J Pharmacol 9(2):239\u2013245. https:\/\/doi.org\/10.1016\/0014-2999(70)90306-7","journal-title":"Eur J Pharmacol"},{"issue":"6142","key":"11_CR55","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/329839a0","volume":"329","author":"M Manning","year":"1987","unstructured":"Manning M, Przybylski JP, Olma A et al (1987) No requirements of cyclic conformation of antagonists in binding to vasopressin receptors. Nature 329(6142):839\u2013840. https:\/\/doi.org\/10.1038\/329839a0","journal-title":"Nature"},{"issue":"11","key":"11_CR56","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1021\/jm00173a027","volume":"33","author":"M Manning","year":"1990","unstructured":"Manning M, Stoev S, Kolodziejczyk A et al (1990) Design of potent and selective linear antagonists of vasopressor (V1-receptor) responses to vasopressin. J Med Chem 33(11):3079\u20133086","journal-title":"J Med Chem"},{"key":"11_CR57","first-page":"321","volume":"395","author":"B Chini","year":"1995","unstructured":"Chini B, Mouillac B, Ala Y et al (1995) Molecular basis for agonist selectivity in the vasopressin\/oxytocin receptor family. Adv Exp Med Biol 395:321\u2013328","journal-title":"Adv Exp Med Biol"},{"issue":"10","key":"11_CR58","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1111\/j.1471-0528.1999.tb08112.x","volume":"106","author":"M Akerlund","year":"1999","unstructured":"Akerlund M, Bossmar T, Brouard R et al (1999) Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women. Br J Obstet Gynaecol 106(10):1047\u20131053","journal-title":"Br J Obstet Gynaecol"},{"issue":"12","key":"11_CR59","doi-asserted-by":"publisher","first-page":"5306","DOI":"10.1021\/jm500365s","volume":"57","author":"K Wisniewski","year":"2014","unstructured":"Wisniewski K, Alagarsamy S, Galyean R et al (2014) New, potent, and selective peptidic oxytocin receptor agonists. J Med Chem 57(12):5306\u20135317. https:\/\/doi.org\/10.1021\/jm500365s","journal-title":"J Med Chem"},{"key":"11_CR60","first-page":"522","volume":"57","author":"R Abdul-Karim","year":"1961","unstructured":"Abdul-Karim R, Assali NS (1961) Renal function in human pregnancy. V. Effects of oxytocin on renal hemodynamics and water and electrolyte excretion. J Lab Clin Med 57:522\u2013532","journal-title":"J Lab Clin Med"},{"issue":"5","key":"11_CR61","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/j.1552-6909.2002.tb00079.x","volume":"31","author":"PL Ruchala","year":"2002","unstructured":"Ruchala PL, Metheny N, Essenpreis H et al (2002) Current practice in oxytocin dilution and fluid administration for induction of labor. J Obstet Gynecol Neonatal Nurs 31(5):545\u2013550. https:\/\/doi.org\/10.1111\/j.1552-6909.2002.tb00079.x","journal-title":"J Obstet Gynecol Neonatal Nurs"},{"issue":"3","key":"11_CR62","first-page":"225","volume":"30","author":"DB Seifer","year":"1985","unstructured":"Seifer DB, Sandberg EC, Ueland K et al (1985) Water intoxication and hyponatremic encephalopathy from the use of an oxytocin nasal spray. A case report. J Reprod Med 30(3):225\u2013228","journal-title":"J Reprod Med"},{"issue":"3","key":"11_CR63","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/0306-4530(87)90009-6","volume":"12","author":"M Ansseau","year":"1987","unstructured":"Ansseau M, Legros JJ, Mormont C et al (1987) Intranasal oxytocin in obsessive-compulsive disorder. Psychoneuroendocrinology 12(3):231\u2013236","journal-title":"Psychoneuroendocrinology"},{"issue":"9001","key":"11_CR64","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S0140-6736(96)91325-2","volume":"347","author":"B. Mayer-Hubner","year":"1996","unstructured":"Mayer-Hubner B (1996) Pseudotumour cerebri from intranasal oxytocin and excessive fluid intake. Lancet 347(9001):623. https:\/\/doi.org\/10.1016\/S0140-6736(96)91325-2","journal-title":"The Lancet"},{"issue":"11","key":"11_CR65","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1111\/bph.12613","volume":"171","author":"C Hicks","year":"2014","unstructured":"Hicks C, Ramos L, Reekie T et al (2014) Body temperature and cardiac changes induced by peripherally administered oxytocin, vasopressin and the non-peptide oxytocin receptor agonist WAY 267,464: a biotelemetry study in rats. Br J Pharmacol 171(11):2868\u20132887. https:\/\/doi.org\/10.1111\/bph.12613","journal-title":"Br J Pharmacol"},{"issue":"6","key":"11_CR66","first-page":"701","volume":"56","author":"RD Leake","year":"1980","unstructured":"Leake RD, Weitzman RE, Fisher DA (1980) Pharmacokinetics of oxytocin in the human subject. Obstet Gynecol 56(6):701\u2013704","journal-title":"Obstet Gynecol"},{"issue":"2","key":"11_CR67","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1055\/s-0029-1210444","volume":"85","author":"R Landgraf","year":"1985","unstructured":"Landgraf R (1985) Plasma oxytocin concentrations in man after different routes of administration of synthetic oxytocin. Exp Clin Endocrinol 85(2):245\u2013248. https:\/\/doi.org\/10.1055\/s-0029-1210444","journal-title":"Exp Clin Endocrinol"},{"issue":"1","key":"11_CR68","first-page":"R21","volume":"259","author":"S Thornton","year":"1990","unstructured":"Thornton S, Davison JM, Baylis PH (1990) Effect of human pregnancy on metabolic clearance rate of oxytocin. Am J Phys 259(1. Pt 2):R21\u2013R24","journal-title":"Am J Phys"},{"issue":"2","key":"11_CR69","first-page":"783","volume":"264","author":"S Lundin","year":"1993","unstructured":"Lundin S, Broeders A, Ohlin M et al (1993) Pharmacokinetic and pharmacologic properties of antiuterotonic oxytocin analogs in the rat. J Pharmacol Exp Ther 264(2):783\u2013788","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"11_CR70","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/0003-9861(92)90007-J","volume":"292","author":"Masafumi Tsujimoto","year":"1992","unstructured":"Tsujimoto M, Mizutani S, Adachi H et al (1992) Identification of human placental leucine aminopeptidase as oxytocinase. Arch Biochem Biophys 292(2):388\u2013392. https:\/\/doi.org\/10.1016\/0003-9861(92)90007-J","journal-title":"Archives of Biochemistry and Biophysics"},{"issue":"15","key":"11_CR71","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/S0024-3205(00)00451-3","volume":"66","author":"Noboru Yamahara","year":"2000","unstructured":"Yamahara N, Nomura S, Suzuki T et al (2000) Placental leucine aminopeptidase\/oxytocinase in maternal serum and placenta during normal pregnancy. Life Sci 66(15):1401\u20131410. https:\/\/doi.org\/10.1016\/S0024-3205(00)00451-3","journal-title":"Life Sciences"},{"issue":"5","key":"11_CR72","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.npep.2012.07.001","volume":"46","author":"A Gossen","year":"2012","unstructured":"Gossen A, Hahn A, Westphal L et al (2012) Oxytocin plasma concentrations after single intranasal oxytocin administration\u2014a study in healthy men. Neuropeptides 46(5):211\u2013215. https:\/\/doi.org\/10.1016\/j.npep.2012.07.001","journal-title":"Neuropeptides"},{"issue":"14","key":"11_CR73","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S1359-6446(03)02692-8","volume":"8","author":"WC Shen","year":"2003","unstructured":"Shen WC (2003) Oral peptide and protein delivery: unfulfilled promises? Drug Discov Today 8(14):607\u2013608","journal-title":"Drug Discov Today"},{"issue":"1\u20132","key":"11_CR74","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ijpharm.2013.02.030","volume":"447","author":"J Renukuntla","year":"2013","unstructured":"Renukuntla J, Vadlapudi AD, Patel A et al (2013) Approaches for enhancing oral bioavailability of peptides and proteins. Int J Pharm 447(1\u20132):75\u201393. https:\/\/doi.org\/10.1016\/j.ijpharm.2013.02.030","journal-title":"Int J Pharm"},{"issue":"4","key":"11_CR75","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.bmcl.2012.12.041","volume":"23","author":"JJ Ferrie","year":"2013","unstructured":"Ferrie JJ, Gruskos JJ, Goldwaser AL et al (2013) A comparative protease stability study of synthetic macrocyclic peptides that mimic two endocrine hormones. Bioorg Med Chem Lett 23(4):989\u2013995. https:\/\/doi.org\/10.1016\/j.bmcl.2012.12.041","journal-title":"Bioorg Med Chem Lett"},{"issue":"3","key":"11_CR76","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1021\/mp500809f","volume":"12","author":"J Wang","year":"2015","unstructured":"Wang J, Yadav V, Smart AL et al (2015) Toward oral delivery of biopharmaceuticals: an assessment of the gastrointestinal stability of 17 peptide drugs. Mol Pharm 12(3):966\u2013973. https:\/\/doi.org\/10.1021\/mp500809f","journal-title":"Mol Pharm"},{"issue":"6","key":"11_CR77","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/0196-9781(95)00088-2","volume":"16","author":"A Fjellestad-Paulsen","year":"1995","unstructured":"Fjellestad-Paulsen A, Soderberg-Ahlm C, Lundin S (1995) Metabolism of vasopressin, oxytocin, and their analogues in the human gastrointestinal tract. Peptides 16(6):1141\u20131147","journal-title":"Peptides"},{"issue":"5","key":"11_CR78","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1016\/j.bbagen.2013.02.009","volume":"1830","author":"P Ghezzi","year":"2013","unstructured":"Ghezzi P (2013) Protein glutathionylation in health and disease. Biochim Biophys Acta 1830(5):3165\u20133172. https:\/\/doi.org\/10.1016\/j.bbagen.2013.02.009","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"11_CR79","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/0006-8993(83)90478-X","volume":"262","author":"Wim B.J. Mens","year":"1983","unstructured":"Mens WB, Witter A, van Wimersma Greidanus TB (1983) Penetration of neurohypophyseal hormones from plasma into cerebrospinal fluid (CSF): half-times of disappearance of these neuropeptides from CSF. Brain Res 262(1):143\u2013149. https:\/\/doi.org\/10.1016\/0006-8993(83)90478-X","journal-title":"Brain Research"},{"issue":"3","key":"11_CR80","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.biopsych.2015.05.003","volume":"79","author":"G Leng","year":"2016","unstructured":"Leng G, Ludwig M (2016) Intranasal oxytocin: myths and delusions. Biol Psychiatry 79(3):243\u2013250. https:\/\/doi.org\/10.1016\/j.biopsych.2015.05.003","journal-title":"Biol Psychiatry"},{"key":"11_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/srep03440","volume":"3","author":"N Striepens","year":"2013","unstructured":"Striepens N, Kendrick KM, Hanking V et al (2013) Elevated cerebrospinal fluid and blood concentrations of oxytocin following its intranasal administration in humans. Sci Rep 3:3440. https:\/\/doi.org\/10.1038\/srep03440","journal-title":"Sci Rep"},{"issue":"3","key":"11_CR82","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1073\/pnas.1114621109","volume":"109","author":"SW Chang","year":"2012","unstructured":"Chang SW, Barter JW, Ebitz RB et al (2012) Inhaled oxytocin amplifies both vicarious reinforcement and self-reinforcement in rhesus macaques (Macaca mulatta). Proc Natl Acad Sci U S A 109(3):959\u2013964. https:\/\/doi.org\/10.1073\/pnas.1114621109","journal-title":"Proc Natl Acad Sci U S A"},{"key":"11_CR83","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.psyneuen.2014.02.011","volume":"45","author":"ME Modi","year":"2014","unstructured":"Modi ME, Connor-Stroud F, Landgraf R et al (2014) Aerosolized oxytocin increases cerebrospinal fluid oxytocin in rhesus macaques. Psychoneuroendocrinology 45:49\u201357. https:\/\/doi.org\/10.1016\/j.psyneuen.2014.02.011","journal-title":"Psychoneuroendocrinology"},{"issue":"3","key":"11_CR84","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1067\/mob.2002.121104","volume":"186","author":"JW Gard","year":"2002","unstructured":"Gard JW, Alexander JM, Bawdon RE et al (2002) Oxytocin preparation stability in several common obstetric intravenous solutions. Am J Obstet Gynecol 186(3):496\u2013498","journal-title":"Am J Obstet Gynecol"},{"issue":"16","key":"11_CR85","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1080\/10826070600864742","volume":"29","author":"V Kumar","year":"2006","unstructured":"Kumar V, Madabushi R, Derendorf H et al (2006) Development and validation of an HPLC method for oxytocin in Ringer's Lactate and its application in stability analysis. J Liq Chromatogr Relat Technol 29(16):2353\u20132365","journal-title":"J Liq Chromatogr Relat Technol"},{"issue":"2","key":"11_CR86","first-page":"156","volume":"10","author":"LA Trissel","year":"2006","unstructured":"Trissel LA, Zhang Y, Douglass K et al (2006) Extended stability of oxytocin in common infusion solutions. Int J Pharm Compd 10(2):156\u2013158","journal-title":"Int J Pharm Compd"},{"issue":"1","key":"11_CR87","first-page":"49","volume":"6","author":"G Kaushal","year":"2012","unstructured":"Kaushal G, Sayre BE, Prettyman T (2012) Stability-indicating HPLC method for the determination of the stability of oxytocin parenteral solutions prepared in polyolefin bags. Drug Discov Ther 6(1):49\u201354","journal-title":"Drug Discov Ther"},{"issue":"2","key":"11_CR88","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1208\/s12248-011-9268-7","volume":"13","author":"C Avanti","year":"2011","unstructured":"Avanti C, Amorij JP, Setyaningsih D et al (2011) A new strategy to stabilize oxytocin in aqueous solutions: I. The effects of divalent metal ions and citrate buffer. AAPS J 13(2):284\u2013290. https:\/\/doi.org\/10.1208\/s12248-011-9268-7","journal-title":"AAPS J"},{"issue":"3","key":"11_CR89","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1021\/mp200622z","volume":"9","author":"C Avanti","year":"2012","unstructured":"Avanti C, Permentier HP, Dam A et al (2012) A new strategy to stabilize oxytocin in aqueous solutions: II. Suppression of cysteine-mediated intermolecular reactions by a combination of divalent metal ions and citrate. Mol Pharm 9(3):554\u2013562. https:\/\/doi.org\/10.1021\/mp200622z","journal-title":"Mol Pharm"},{"issue":"7","key":"11_CR90","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1007\/s11095-009-9878-2","volume":"26","author":"A Hawe","year":"2009","unstructured":"Hawe A, Poole R, Romeijn S et al (2009) Towards heat-stable oxytocin formulations: analysis of degradation kinetics and identification of degradation products. Pharm Res 26(7):1679\u20131688. https:\/\/doi.org\/10.1007\/s11095-009-9878-2","journal-title":"Pharm Res"},{"issue":"4","key":"11_CR91","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/bip.22260","volume":"100","author":"K Wisniewski","year":"2013","unstructured":"Wisniewski K, Finnman J, Flipo M et al (2013) On the mechanism of degradation of oxytocin and its analogues in aqueous solution. Biopolymers 100(4):408\u2013421. https:\/\/doi.org\/10.1002\/bip.22260","journal-title":"Biopolymers"},{"key":"11_CR92","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S0079-6123(08)00437-8","volume":"170","author":"M Manning","year":"2008","unstructured":"Manning M, Stoev S, Chini B et al (2008) Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog Brain Res 170:473\u2013512. https:\/\/doi.org\/10.1016\/S0079-6123(08)00437-8","journal-title":"Prog Brain Res"},{"key":"11_CR93","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S0079-6123(08)00438-X","volume":"170","author":"B Chini","year":"2008","unstructured":"Chini B, Manning M, Guillon G (2008) Affinity and efficacy of selective agonists and antagonists for vasopressin and oxytocin receptors: an \u201ceasy guide\u201d to receptor pharmacology. Prog Brain Res 170:513\u2013517. https:\/\/doi.org\/10.1016\/S0079-6123(08)00438-X","journal-title":"Prog Brain Res"},{"issue":"6369","key":"11_CR94","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/356526a0","volume":"356","author":"T Kimura","year":"1992","unstructured":"Kimura T, Tanizawa O, Mori K et al (1992) Structure and expression of a human oxytocin receptor. Nature 356(6369):526\u2013529. https:\/\/doi.org\/10.1038\/356526a0","journal-title":"Nature"},{"issue":"1\u20132","key":"11_CR95","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/0167-0115(93)90185-B","volume":"45","author":"T Kimura","year":"1993","unstructured":"Kimura T, Azuma C, Takemura M et al (1993) Molecular cloning of a human oxytocin receptor. Regul Pept 45(1\u20132):73\u201377","journal-title":"Regul Pept"},{"issue":"5","key":"11_CR96","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1016\/S0021-9258(17)41863-1","volume":"269","author":"M Thibonnier","year":"1994","unstructured":"Thibonnier M, Auzan C, Madhun Z et al (1994) Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor. J Biol Chem 269(5):3304\u20133310","journal-title":"J Biol Chem"},{"issue":"43","key":"11_CR97","doi-asserted-by":"crossref","first-page":"27088","DOI":"10.1016\/S0021-9258(18)47129-3","volume":"269","author":"T Sugimoto","year":"1994","unstructured":"Sugimoto T, Saito M, Mochizuki S et al (1994) Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor. J Biol Chem 269(43):27088\u201327092","journal-title":"J Biol Chem"},{"issue":"17","key":"11_CR98","doi-asserted-by":"crossref","first-page":"11783","DOI":"10.1016\/S0021-9258(19)49766-4","volume":"267","author":"M Birnbaumer","year":"1992","unstructured":"Birnbaumer M, Antaramian A, Themmen AP et al (1992) Desensitization of the human V2 vasopressin receptor. Homologous effects in the absence of heterologous desensitization. J Biol Chem 267(17):11783\u201311788","journal-title":"J Biol Chem"},{"issue":"6376","key":"11_CR99","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/357336a0","volume":"357","author":"SJ Lolait","year":"1992","unstructured":"Lolait SJ, O'Carroll AM, McBride OW et al (1992) Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus. Nature 357(6376):336\u2013339. https:\/\/doi.org\/10.1038\/357336a0","journal-title":"Nature"},{"issue":"1","key":"11_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/(SICI)1098-1128(199701)17:1<1::AID-MED1>3.0.CO;2-5","volume":"17","author":"RM Freidinger","year":"1997","unstructured":"Freidinger RM, Pettibone DJ (1997) Small molecule ligands for oxytocin and vasopressin receptors. Med Res Rev 17(1):1\u201316. https:\/\/doi.org\/10.1002\/(SICI)1098-1128(199701)17:1<1::AID-MED1>3.0.CO;2-5","journal-title":"Med Res Rev"},{"issue":"18","key":"11_CR101","doi-asserted-by":"publisher","first-page":"6525","DOI":"10.1021\/jm901812z","volume":"53","author":"AD Borthwick","year":"2010","unstructured":"Borthwick AD (2010) Oral oxytocin antagonists. J Med Chem 53(18):6525\u20136538. https:\/\/doi.org\/10.1021\/jm901812z","journal-title":"J Med Chem"},{"issue":"17","key":"11_CR102","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.1016\/j.bmcl.2004.04.107","volume":"14","author":"GR Pitt","year":"2004","unstructured":"Pitt GR, Batt AR, Haigh RM et al (2004) Non-peptide oxytocin agonists. Bioorg Med Chem Lett 14(17):4585\u20134589. https:\/\/doi.org\/10.1016\/j.bmcl.2004.04.107","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"11_CR103","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.neuropharm.2009.07.016","volume":"58","author":"RH Ring","year":"2010","unstructured":"Ring RH, Schechter LE, Leonard SK et al (2010) Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist. Neuropharmacology 58(1):69\u201377. https:\/\/doi.org\/10.1016\/j.neuropharm.2009.07.016","journal-title":"Neuropharmacology"},{"key":"11_CR104","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1046\/j.1471-0528.2003.00024.x","volume":"110 Suppl 20","author":"AM Blanks","year":"2003","unstructured":"Blanks AM, Thornton S (2003) The role of oxytocin in parturition. BJOG 110 Suppl 20:46\u201351","journal-title":"BJOG"},{"issue":"3","key":"11_CR105","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1080\/gye.17.3.261.267","volume":"17","author":"T Laudanski","year":"2003","unstructured":"Laudanski T, Pierzynski P (2003) Oxytocin and fetal membranes in preterm labor: current concepts and clinical implication. Gynecol Endocrinol 17(3):261\u2013267","journal-title":"Gynecol Endocrinol"},{"issue":"5","key":"11_CR106","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/S0029-7844(97)00056-2","volume":"89","author":"GG Zeeman","year":"1997","unstructured":"Zeeman GG, Khan-Dawood FS, Dawood MY (1997) Oxytocin and its receptor in pregnancy and parturition: current concepts and clinical implications. Obstet Gynecol 89(5. Pt 2):873\u2013883","journal-title":"Obstet Gynecol"},{"issue":"6","key":"11_CR107","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/0002-9378(80)90455-X","volume":"136","author":"Katsuhiko Takahashi","year":"1980","unstructured":"Takahashi K, Diamond F, Bieniarz J et al (1980) Uterine contractility and oxytocin sensitivity in preterm, term, and postterm pregnancy. Am J Obstet Gynecol 136(6):774\u2013779. https:\/\/doi.org\/10.1016\/0002-9378(80)90455-X","journal-title":"American Journal of Obstetrics and Gynecology"},{"issue":"2","key":"11_CR108","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1210\/endo.137.2.8593830","volume":"137","author":"T Kimura","year":"1996","unstructured":"Kimura T, Takemura M, Nomura S et al (1996) Expression of oxytocin receptor in human pregnant myometrium. Endocrinology 137(2):780\u2013785. https:\/\/doi.org\/10.1210\/endo.137.2.8593830","journal-title":"Endocrinology"},{"issue":"15","key":"11_CR109","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.2174\/0929867033457331","volume":"10","author":"MK Schwarz","year":"2003","unstructured":"Schwarz MK, Page P (2003) Preterm labour: an overview of current and emerging therapeutics. Curr Med Chem 10(15):1441\u20131468","journal-title":"Curr Med Chem"},{"issue":"4","key":"11_CR110","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1053\/sper.2001.27548","volume":"25","author":"JN Robinson","year":"2001","unstructured":"Robinson JN, Regan JA, Norwitz ER (2001) The epidemiology of preterm labor. Semin Perinatol 25(4):204\u2013214","journal-title":"Semin Perinatol"},{"issue":"2","key":"11_CR111","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/0303-7207(81)90086-1","volume":"22","author":"WH Sawyer","year":"1981","unstructured":"Sawyer WH, Grzonka Z, Manning M (1981) Neurohypophysial peptides. Design of tissue-specific agonists and antagonists. Mol Cell Endocrinol 22(2):117\u2013134. https:\/\/doi.org\/10.1016\/0303-7207(81)90086-1","journal-title":"Mol Cell Endocrinol"},{"key":"11_CR112","unstructured":"Lebl M (1987) Analogs with inhibitory properties. In: Jost K, Lebl M, Brtnik F (eds) CRC Handbook of neurohypophyseal hormone analogs, vol 2, pt 1. CRC Press, Boca Raton, pp 17\u201374"},{"key":"11_CR113","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0196-9781(87)90168-9","volume":"8","author":"VJ Hruby","year":"1987","unstructured":"Hruby VJ, Smith CW (1987) Structure-activity relationships of neurohypophyseal peptides. Peptides (N Y) 8:77\u2013207","journal-title":"Peptides (N Y)"},{"issue":"6","key":"11_CR114","first-page":"617","volume":"114","author":"M Manning","year":"1989","unstructured":"Manning M, Sawyer WH (1989) Discovery, development, and some uses of vasopressin and oxytocin antagonists. J Lab Clin Med 114(6):617\u2013632","journal-title":"J Lab Clin Med"},{"issue":"1\u20134","key":"11_CR115","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3109\/10799899309073655","volume":"13","author":"M Manning","year":"1993","unstructured":"Manning M, Sawyer WH (1993) Design, synthesis and some uses of receptor-specific agonists and antagonists of vasopressin and oxytocin. J Recept Res 13(1\u20134):195\u2013214","journal-title":"J Recept Res"},{"key":"11_CR116","first-page":"559","volume":"395","author":"M Manning","year":"1995","unstructured":"Manning M, Cheng LL, Klis WA et al (1995) Advances in the design of selective antagonists, potential tocolytics, and radioiodinated ligands for oxytocin receptors. Adv Exp Med Biol 395:559\u2013583","journal-title":"Adv Exp Med Biol"},{"key":"11_CR117","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/350546","volume":"2011","author":"N Vrachnis","year":"2011","unstructured":"Vrachnis N, Malamas FM, Sifakis S et al (2011) The oxytocin-oxytocin receptor system and its antagonists as tocolytic agents. Int J Endocrinol 2011:350546. https:\/\/doi.org\/10.1155\/2011\/350546","journal-title":"Int J Endocrinol"},{"issue":"4","key":"11_CR118","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/j.1365-2826.2012.02303.x","volume":"24","author":"M Manning","year":"2012","unstructured":"Manning M, Misicka A, Olma A et al (2012) Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics. J Neuroendocrinol 24(4):609\u2013628. https:\/\/doi.org\/10.1111\/j.1365-2826.2012.02303.x","journal-title":"J Neuroendocrinol"},{"key":"11_CR119","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1021\/ja01502a034","volume":"82","author":"HD Law","year":"1960","unstructured":"Law HD, du Vigneaud V (1960) Synthesis of 2-(p-methoxyphenyl)alanine oxytocin (O-methyloxytocin) and some observations on its pharmacological behavior. J Am Chem Soc 82:4579\u20134581. https:\/\/doi.org\/10.1021\/ja01502a034","journal-title":"J Am Chem Soc"},{"issue":"5","key":"11_CR120","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1021\/jm00323a001","volume":"9","author":"H Schulz","year":"1966","unstructured":"Schulz H, Du Vigneaud V (1966) Synthesis of 1-L-penicillamine-oxytocin, 1-D-penicillamine-oxytocin, and 1-deaminopenicillamine-oxytocin, potent inhibitors of the oxytocic response of oxytocin. J Med Chem 9(5):647\u2013650","journal-title":"J Med Chem"},{"issue":"2","key":"11_CR121","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1021\/jm00272a001","volume":"15","author":"RJ Vavrek","year":"1972","unstructured":"Vavrek RJ, Ferger MF, Allen GA et al (1972) Synthesis of three oxytocin analogs related to (1-deaminopenicillamine)oxytocin possessing antioxytocic activity. J Med Chem 15(2):123\u2013126","journal-title":"J Med Chem"},{"issue":"3","key":"11_CR122","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1021\/jm00237a015","volume":"18","author":"JJ Nestor Jr","year":"1975","unstructured":"Nestor JJ Jr, Ferger MF, du Vigneaud V (1975) [1-Beta-mercapto-beta,beta-pentamethylenepropionic acid]oxytocin, a potent inhibitor of oxytocin. J Med Chem 18(3):284\u2013287","journal-title":"J Med Chem"},{"issue":"5","key":"11_CR123","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1021\/jm00191a019","volume":"22","author":"J Lowbridge","year":"1979","unstructured":"Lowbridge J, Manning M, Seto J et al (1979) Synthetic antagonists of in vivo responses by the rat uterus to oxytocin. J Med Chem 22(5):565\u2013569","journal-title":"J Med Chem"},{"issue":"1","key":"11_CR124","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1210\/endo-106-1-81","volume":"106","author":"WH Sawyer","year":"1980","unstructured":"Sawyer WH, Haldar J, Gazis D et al (1980) The design of effective in vivo antagonists of rat uterus and milk ejection responses to oxytocin. Endocrinology 106(1):81\u201391. https:\/\/doi.org\/10.1210\/endo-106-1-81","journal-title":"Endocrinology"},{"issue":"5","key":"11_CR125","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/j.1399-3011.1980.tb02962.x","volume":"16","author":"K Bankowski","year":"1980","unstructured":"Bankowski K, Manning M, Seto J et al (1980) Design and synthesis of potent in vivo antagonists of oxytocin. Int J Pept Protein Res 16(5):382\u2013391","journal-title":"Int J Pept Protein Res"},{"issue":"7","key":"11_CR126","first-page":"1654","volume":"42","author":"OA Kaurov","year":"1972","unstructured":"Kaurov OA, Martynov VF, Mikhailov YD et al (1972) Synthesis of new oxytocin analogs modified in position 2. Zh Obshch Khim 42(7):1654","journal-title":"Zh Obshch Khim"},{"issue":"5","key":"11_CR127","first-page":"619","volume":"4","author":"OA Kaurov","year":"1978","unstructured":"Kaurov OA, Mikhailov YD, Smirnova MP (1978) Structure-uterotonic activity relationship for oxytocin analogs modified in position 2. Bioorg Khim 4(5):619\u2013627","journal-title":"Bioorg Khim"},{"key":"11_CR128","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1515\/9783111694344-094","volume-title":"Prague, Czechoslovakia, August 29\u2013September 3, 1982","author":"Michal Lebl","year":"1983","unstructured":"Lebl M, Barth T, Servitova L et al (1982) Analogs of neurohypophysial hormones containing a D-amino acid in position 2. In: Peptides, Proceedings of the 17th European Peptide Symposium. de Gruyter, Berlin, pp 457\u2013460"},{"issue":"1","key":"11_CR129","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1135\/cccc19850132","volume":"50","author":"M Lebl","year":"1985","unstructured":"Lebl M, Barth T, Servitova L et al (1985) Amino acids and peptides. CXC. Oxytocin analogs with inhibitory properties, containing in position 2 a hydrophobic amino acid of D-configuration. Collect Czechoslov Chem Commun 50(1):132\u2013145. https:\/\/doi.org\/10.1135\/cccc19850132","journal-title":"Collect Czechoslov Chem Commun"},{"issue":"2","key":"11_CR130","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3181\/00379727-185-42533","volume":"185","author":"WY Chan","year":"1987","unstructured":"Chan WY, Rockway TW, Hruby VJ (1987) Long-acting oxytocin antagonists: effects of 2-D-stereoisomer substitution on antagonistic potency and duration of action. Proc Soc Exp Biol Med 185(2):187\u2013192","journal-title":"Proc Soc Exp Biol Med"},{"issue":"2","key":"11_CR131","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1021\/jm00106a027","volume":"34","author":"G Flouret","year":"1991","unstructured":"Flouret G, Brieher W, Mahan K et al (1991) Design of potent oxytocin antagonists featuring D-tryptophan at position 2. J Med Chem 34(2):642\u2013646","journal-title":"J Med Chem"},{"issue":"7","key":"11_CR132","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/psc.390","volume":"8","author":"G Flouret","year":"2002","unstructured":"Flouret G, Majewski T, Balaspiri L et al (2002) Antagonists of oxytocin featuring replacement with modified beta-mercaptopropionic acids at position 1. J Pept Sci 8(7):314\u2013326. https:\/\/doi.org\/10.1002\/psc.390","journal-title":"J Pept Sci"},{"issue":"6","key":"11_CR133","first-page":"763","volume":"18","author":"TG Ahn","year":"2004","unstructured":"Ahn TG, Han SJ, Cho YS et al (2004) In vivo activity of the potent oxytocin antagonist on uterine activity in the rat. In Vivo 18(6):763\u2013766","journal-title":"In Vivo"},{"issue":"5","key":"11_CR134","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1071-5576(98)00021-5","volume":"5","author":"MD Fejgin","year":"1998","unstructured":"Fejgin MD, Pak SC, Flouret G et al (1998) Comparison of the in vivo activity of different oxytocin antagonists in the pregnant baboon. J Soc Gynecol Investig 5(5):251\u2013254. https:\/\/doi.org\/10.1016\/S1071-5576(98)00021-5","journal-title":"J Soc Gynecol Investig"},{"issue":"1","key":"11_CR135","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1159\/000064692","volume":"54","author":"CH Song","year":"2002","unstructured":"Song CH, So GY, Pak SC et al (2002) Comparison of oxytocin and oxytocin antagonist metabolism in the plasma of pregnant humans and baboons. Gynecol Obstet Investig 54(1):21\u201325. https:\/\/doi.org\/10.1159\/000064692","journal-title":"Gynecol Obstet Investig"},{"issue":"6","key":"11_CR136","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/psc.471","volume":"9","author":"G Flouret","year":"2003","unstructured":"Flouret G, Chaloin O, Slaninova J (2003) Analogues of a potent oxytocin antagonist with truncated C-terminus or shorter amino acid side chain of the basic amino acid at position 8. J Pept Sci 9(6):393\u2013401. https:\/\/doi.org\/10.1002\/psc.471","journal-title":"J Pept Sci"},{"issue":"5","key":"11_CR137","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/psc.733","volume":"12","author":"G Flouret","year":"2006","unstructured":"Flouret G, Chaloin O, Borovickova L et al (2006) Analogues of oxytocin antagonists bearing a ureido group in the amino acid side chain at position 4 or 5. J Pept Sci 12(5):347\u2013353. https:\/\/doi.org\/10.1002\/psc.733","journal-title":"J Pept Sci"},{"issue":"9","key":"11_CR138","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1135\/cccc19842012","volume":"49","author":"M Lebl","year":"1984","unstructured":"Lebl M, Barth T, Servitova L et al (1984) Amino acids and peptides. CLXXXVI. Synthesis and properties of carba-6 analogs of oxytocin containing a deaminopenicillamine residue in position 1. Collect Czechoslov Chem Commun 49(9):2012\u20132023. https:\/\/doi.org\/10.1135\/cccc19842012","journal-title":"Collect Czechoslov Chem Commun"},{"issue":"6","key":"11_CR139","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1135\/cccc19921335","volume":"57","author":"Z Prochazka","year":"1992","unstructured":"Prochazka Z, Slaninova J, Barth T et al (1992) Amino acids and peptides. CCXXIX. Analogs of deamino carba oxytocin with inhibitory properties; synthesis and biological activities. Collect Czechoslov Chem Commun 57(6):1335\u20131344. https:\/\/doi.org\/10.1135\/cccc19921335","journal-title":"Collect Czechoslov Chem Commun"},{"issue":"10","key":"11_CR140","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/psc.667","volume":"11","author":"M Manning","year":"2005","unstructured":"Manning M, Cheng LL, Stoev S et al (2005) Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban. J Pept Sci 11(10):593\u2013608. https:\/\/doi.org\/10.1002\/psc.667","journal-title":"J Pept Sci"},{"issue":"2","key":"11_CR141","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1021\/jm00122a016","volume":"32","author":"M Manning","year":"1989","unstructured":"Manning M, Kruszynski M, Bankowski K et al (1989) Solid-phase synthesis of 16 potent (selective and nonselective) in vivo antagonists of oxytocin. J Med Chem 32(2):382\u2013391","journal-title":"J Med Chem"},{"issue":"5","key":"11_CR142","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1007\/s00726-009-0372-2","volume":"38","author":"V Magafa","year":"2010","unstructured":"Magafa V, Borovickova L, Slaninova J et al (2010) Synthesis and biological activity of oxytocin analogues containing unnatural amino acids in position 9: structure activity study. Amino Acids 38(5):1549\u20131559. https:\/\/doi.org\/10.1007\/s00726-009-0372-2","journal-title":"Amino Acids"},{"issue":"29","key":"11_CR143","doi-asserted-by":"publisher","first-page":"26931","DOI":"10.1074\/jbc.M102073200","volume":"276","author":"C Breton","year":"2001","unstructured":"Breton C, Chellil H, Kabbaj-Benmansour M et al (2001) Direct identification of human oxytocin receptor-binding domains using a photoactivatable cyclic peptide antagonist: comparison with the human V1a vasopressin receptor. J Biol Chem 276(29):26931\u201326941. https:\/\/doi.org\/10.1074\/jbc.M102073200","journal-title":"J Biol Chem"},{"issue":"2","key":"11_CR144","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/0014-2999(88)90778-9","volume":"147","author":"J Elands","year":"1988","unstructured":"Elands J, Barberis C, Jard S et al (1988) 125I-labelled d(CH2)5[Tyr(Me)2,Thr4,Tyr-NH2(9)]OVT: a selective oxytocin receptor ligand. Eur J Pharmacol 147(2):197\u2013207. https:\/\/doi.org\/10.1016\/0014-2999(88)90778-9","journal-title":"Eur J Pharmacol"},{"issue":"18","key":"11_CR145","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1021\/jm010125u","volume":"44","author":"E Carnazzi","year":"2001","unstructured":"Carnazzi E, Aumelas A, Mouillac B et al (2001) Design, synthesis and pharmacological characterization of a potent radioiodinated and photoactivatable peptidic oxytocin antagonist. J Med Chem 44(18):3022\u20133030","journal-title":"J Med Chem"},{"issue":"2","key":"11_CR146","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1677\/joe.0.0880173","volume":"88","author":"P Melin","year":"1981","unstructured":"Melin P, Vilhardt H, Lindeberg G et al (1981) Inhibitory effect of O-alkylated analogues of oxytocin and vasopressin on human and rat myometrial activity. J Endocrinol 88(2):173\u2013180","journal-title":"J Endocrinol"},{"issue":"8","key":"11_CR147","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/j.1471-0528.1983.tb09303.x","volume":"90","author":"M Akerlund","year":"1983","unstructured":"Akerlund M, Kostrzewska A, Laudanski T et al (1983) Vasopressin effects on isolated non-pregnant myometrium and uterine arteries and their inhibition by deamino-ethyl-lysine-vasopressin and deamino-ethyl-oxytocin. Br J Obstet Gynaecol 90(8):732\u2013738","journal-title":"Br J Obstet Gynaecol"},{"issue":"3","key":"11_CR148","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/00006250-198309000-00009","volume":"62","author":"M Akerlund","year":"1983","unstructured":"Akerlund M, Stromberg P, Forsling ML et al (1983) Inhibition of vasopressin effects on the uterus by a synthetic analogue. Obstet Gynecol 62(3):309\u2013312","journal-title":"Obstet Gynecol"},{"key":"11_CR149","unstructured":"Melin P, Trojnar J, Vilhardt H et al (1983) Uterotonic oxytocin and vasopressin antagonists with minimal structure modifications. In: Hruby VJ, Rich DH (eds) Peptides. Structure and function. Proceedings of the Eight American Peptide Symposium, Tuscon, AZ, USA. Pierce Chem. Co., pp 361\u2013364"},{"issue":"1","key":"11_CR150","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1677\/joe.0.1110125","volume":"111","author":"P. Melin","year":"1986","unstructured":"Melin P, Trojnar J, Johansson B et al (1986) Synthetic antagonists of the myometrial response to vasopressin and oxytocin. J Endocrinol 111 (1):125\u2013131","journal-title":"Journal of Endocrinology"},{"issue":"5","key":"11_CR151","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1067\/mob.2000.95834","volume":"182","author":"R Romero","year":"2000","unstructured":"Romero R, Sibai BM, Sanchez-Ramos L et al (2000) An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double-blind, placebo-controlled trial with tocolytic rescue. Am J Obstet Gynecol 182(5):1173\u20131183. https:\/\/doi.org\/10.1067\/mob.2000.95834","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"11_CR152","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1067\/mob.2000.105816","volume":"182","author":"GJ Valenzuela","year":"2000","unstructured":"Valenzuela GJ, Sanchez-Ramos L, Romero R et al (2000) Maintenance treatment of preterm labor with the oxytocin antagonist atosiban. The Atosiban PTL-098 Study Group. Am J Obstet Gynecol 182(5):1184\u20131190. https:\/\/doi.org\/10.1067\/mob.2000.105816","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"11_CR153","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2165\/00003495-200464040-00003","volume":"64","author":"V Tsatsaris","year":"2004","unstructured":"Tsatsaris V, Carbonne B, Cabrol D (2004) Atosiban for preterm labour. Drugs 64(4):375\u2013382","journal-title":"Drugs"},{"issue":"2","key":"11_CR154","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1742-1241.2003.tb10440.x","volume":"57","author":"P Husslein","year":"2003","unstructured":"Husslein P, Quartarolo JP (2003) Review of clinical experience with atosiban and the Tractocile Efficacy Assessment Survey in Europe (TREASURE) study protocol. Int J Clin Pract 57(2):121\u2013127","journal-title":"Int J Clin Pract"},{"issue":"3\u20134","key":"11_CR155","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1399-3011.1995.tb00596.x","volume":"46","author":"M Manning","year":"1995","unstructured":"Manning M, Miteva K, Pancheva S et al (1995) Design and synthesis of highly selective in vitro and in vivo uterine receptor antagonists of oxytocin: comparisons with Atosiban. Int J Pept Protein Res 46(3\u20134):244\u2013252","journal-title":"Int J Pept Protein Res"},{"issue":"5","key":"11_CR156","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/S0002-9378(96)70050-9","volume":"175","author":"W.Y. Chan","year":"1996","unstructured":"Chan WY, Wo NC, Manning M (1996) The role of oxytocin receptors and vasopressin V1a receptors in uterine contractions in rats: implications for tocolytic therapy with oxytocin antagonists. Am J Obstet Gynecol 175(5):1331\u20131335. https:\/\/doi.org\/10.1016\/S0002-9378(96)70050-9","journal-title":"American Journal of Obstetrics and Gynecology"},{"issue":"2","key":"11_CR157","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1080\/09513590400021144","volume":"20","author":"M Steinwall","year":"2005","unstructured":"Steinwall M, Bossmar T, Brouard R et al (2005) The effect of relcovaptan (SR 49059), an orally active vasopressin V1a receptor antagonist, on uterine contractions in preterm labor. Gynecol Endocrinol 20(2):104\u2013109. https:\/\/doi.org\/10.1080\/09513590400021144","journal-title":"Gynecol Endocrinol"},{"key":"11_CR158","unstructured":"Stoev S, Cheng LL, Manning M et al (2001) Design of tocolytic oxytocin antagonists which are more selective than Atosiban in rat bioassays and in human receptor assays. In: Lebl M, Houghten RA (eds) Peptides: The wave of the future, Proceedings of the Seventeenth American Peptide Symposium, San Diego, CA, USA. American Peptide Society, pp 699\u2013700"},{"issue":"9","key":"11_CR159","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/psc.339","volume":"7","author":"M Manning","year":"2001","unstructured":"Manning M, Stoev S, Cheng LL et al (2001) Design of oxytocin antagonists, which are more selective than atosiban. J Pept Sci 7(9):449\u2013465. https:\/\/doi.org\/10.1002\/psc.339","journal-title":"J Pept Sci"},{"issue":"1","key":"11_CR160","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1021\/ol027160v","volume":"5","author":"JL Stymiest","year":"2003","unstructured":"Stymiest JL, Mitchell BF, Wong S et al (2003) Synthesis of biologically active dicarba analogues of the peptide hormone oxytocin using ring-closing metathesis. Org Lett 5(1):47\u201349. https:\/\/doi.org\/10.1021\/ol027160v","journal-title":"Org Lett"},{"issue":"20","key":"11_CR161","doi-asserted-by":"publisher","first-page":"7799","DOI":"10.1021\/jo050539l","volume":"70","author":"JL Stymiest","year":"2005","unstructured":"Stymiest JL, Mitchell BF, Wong S et al (2005) Synthesis of oxytocin analogues with replacement of sulfur by carbon gives potent antagonists with increased stability. J Org Chem 70(20):7799\u20137809. https:\/\/doi.org\/10.1021\/jo050539l","journal-title":"J Org Chem"},{"issue":"1\u20132","key":"11_CR162","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejphar.2005.01.010","volume":"510","author":"G Gimpl","year":"2005","unstructured":"Gimpl G, Postina R, Fahrenholz F et al (2005) Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and carbetocin. Eur J Pharmacol 510(1\u20132):9\u201316. https:\/\/doi.org\/10.1016\/j.ejphar.2005.01.010","journal-title":"Eur J Pharmacol"},{"issue":"16","key":"11_CR163","doi-asserted-by":"publisher","first-page":"5086","DOI":"10.1021\/bi015990v","volume":"41","author":"Victoria J. Wesley","year":"2002","unstructured":"Wesley VJ, Hawtin SR, Howard HC et al (2002) Agonist-specific, high-affinity binding epitopes are contributed by an arginine in the N-terminus of the human oxytocin receptor. Biochemistry 41(16):5086\u20135092. https:\/\/doi.org\/10.1021\/bi015990v","journal-title":"Biochemistry"},{"key":"11_CR164","unstructured":"Aurell C-J, Melin P, Nilsson A et al (1995) Preparation of peptides exhibiting oxytocin antagonistic activity. WO9502609A1"},{"key":"11_CR165","unstructured":"Nilsson A, Aurell C-J, Ekholm K et al (1996) Synthesis of an oxytocin antagonist\u2014Ferring F 792. In: Ramage R, Epton R (eds) Peptides 1996, Proceedings of the 24th European Peptide Symposium, Edinburgh, Scotland. Mayflower Scientific, pp 683\u2013684"},{"issue":"19","key":"11_CR166","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1016\/s0960-894x(99)00478-3","volume":"9","author":"K Wisniewski","year":"1999","unstructured":"Wisniewski K, Trojnar J, Riviere P et al (1999) The synthesis of a new class of oxytocin antagonists. Bioorg Med Chem Lett 9(19):2801\u20132804. https:\/\/doi.org\/10.1016\/s0960-894x(99)00478-3","journal-title":"Bioorg Med Chem Lett"},{"key":"11_CR167","unstructured":"Wisniewski K, Trojnar J, Haigh R et al (1999) In search for a new class of oxytocin antagonists. In: Bajusz S, Hudecz F (eds) Peptides 1998, Proceedings of the 25th European peptide symposium, Budapest. Akademiai Kiado, pp 518\u2013519"},{"key":"11_CR168","unstructured":"Melin P, Nilsson A, Trojnar J et al (1998) Preparation of heptapeptide alcohol oxytocin analogs. WO9823636A1"},{"issue":"6","key":"11_CR169","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.jsgi.2004.02.008","volume":"11","author":"P Pierzynski","year":"2004","unstructured":"Pierzynski P, Lemancewicz A, Reinheimer T et al (2004) Inhibitory effect of barusiban and atosiban on oxytocin-induced contractions of myometrium from preterm and term pregnant women. J Soc Gynecol Investig 11(6):384\u2013387. https:\/\/doi.org\/10.1016\/j.jsgi.2004.02.008","journal-title":"J Soc Gynecol Investig"},{"issue":"11","key":"11_CR170","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1111\/j.1471-0528.2003.02540.x","volume":"110","author":"L Nilsson","year":"2003","unstructured":"Nilsson L, Reinheimer T, Steinwall M et al (2003) FE 200 440: a selective oxytocin antagonist on the term-pregnant human uterus. BJOG 110(11):1025\u20131028","journal-title":"BJOG"},{"issue":"4","key":"11_CR171","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1210\/jc.2004-2120","volume":"90","author":"TM Reinheimer","year":"2005","unstructured":"Reinheimer TM, Bee WH, Resendez JC et al (2005) Barusiban, a new highly potent and long-acting oxytocin antagonist: pharmacokinetic and pharmacodynamic comparison with atosiban in a cynomolgus monkey model of preterm labor. J Clin Endocrinol Metab 90(4):2275\u20132281. https:\/\/doi.org\/10.1210\/jc.2004-2120","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"11_CR172","doi-asserted-by":"publisher","first-page":"627 e621","DOI":"10.1016\/j.ajog.2009.01.015","volume":"200","author":"S Thornton","year":"2009","unstructured":"Thornton S, Goodwin TM, Greisen G et al (2009) The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol 200(6):627 e621\u2013627 e610. https:\/\/doi.org\/10.1016\/j.ajog.2009.01.015","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"11_CR173","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1002\/hlca.19630460517","volume":"46","author":"S Guttmann","year":"1963","unstructured":"Guttmann S, Boissonnas RA (1963) Synthesis of Ser4-oxytocin, Ala4-oxytocin, Ser5-oxytocin, and Ala5-oxytocin. Helv Chim Acta 46(5):1626\u20131636","journal-title":"Helv Chim Acta"},{"key":"11_CR174","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0021-9258(18)51704-X","volume":"239","author":"V Vigneaud du","year":"1964","unstructured":"du Vigneaud V, Denning GS Jr, Drabarek S et al (1964) The synthesis and pharmacological study of 4-decarboxamido-oxytocin (4-alpha-aminobutyric acid-oxytocin) and 5-decarboxamido-oxytocin (5-alanine-oxytocin). J Biol Chem 239:472\u2013478","journal-title":"J Biol Chem"},{"issue":"2","key":"11_CR175","first-page":"999","volume":"277","author":"WY Chan","year":"1996","unstructured":"Chan WY, Wo NC, Cheng LL et al (1996) Isosteric substitution of Asn5 in antagonists of oxytocin and vasopressin leads to highly selective and potent oxytocin and V1a receptor antagonists: new approaches for the design of potential tocolytics for preterm labor. J Pharmacol Exp Ther 277(2):999\u20131003","journal-title":"J Pharmacol Exp Ther"},{"key":"11_CR176","unstructured":"Cheng LL, Olma A, Klis WA et al (1996) Position 5 modifications of vasopressin and oxytocin antagonists enhance OT receptor selectivity. In: PTP K, Hodges RS (eds) Peptides: Chemistry, structure and biology, Proceedings of the 14th American Peptide Symposium, Columbus, OH, USA. Mayflower Scientific, pp 380\u2013381"},{"issue":"1","key":"11_CR177","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/psc.310010109","volume":"1","author":"M Manning","year":"1995","unstructured":"Manning M, Cheng LL, Stoev S et al (1995) An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin. J Pept Sci 1(1):66\u201379. https:\/\/doi.org\/10.1002\/psc.310010109","journal-title":"J Pept Sci"},{"issue":"6","key":"11_CR178","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1021\/jm00058a011","volume":"36","author":"G Flouret","year":"1993","unstructured":"Flouret G, Majewski T, Brieher W et al (1993) Systematic substitution of an oxytocin antagonist with D-amino acids: unexpected high antagonistic potency of the D-Cys6-substituted analogue. J Med Chem 36(6):747\u2013749","journal-title":"J Med Chem"},{"issue":"3","key":"11_CR179","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1034\/j.1399-3011.2001.00932.x","volume":"58","author":"L Belec","year":"2001","unstructured":"Belec L, Maletinska L, Slaninova J et al (2001) The influence of steric interactions on the conformation and biology of oxytocin. Synthesis and analysis of penicillamine(6)-oxytocin and penicillamine(6)-5-tert-butylproline(7)-oxytocin analogs. J Pept Res 58(3):263\u2013273","journal-title":"J Pept Res"},{"key":"11_CR180","doi-asserted-by":"crossref","unstructured":"Belec L, Slaninova J, Lubell WD (2000) A study of the relationship between biological activity and prolyl amide isomer geometry in oxytocin using 5-tert-butylproline to augment the Cys(6)-Pro(7) amide cis-isomer population. J Med Chem 43(8):1448\u20131455. https:\/\/doi.org\/jm990090m","DOI":"10.1021\/jm990090m"},{"issue":"19","key":"11_CR181","doi-asserted-by":"publisher","first-page":"7331","DOI":"10.1021\/ja00045a001","volume":"114","author":"CK Larive","year":"1992","unstructured":"Larive CK, Guerra L, Rabenstein DL (1992) Cis\/trans conformational equilibrium across the cysteine6-proline peptide bond of oxytocin, arginine vasopressin, and lysine vasopressin. J Am Chem Soc 114(19):7331\u20137337","journal-title":"J Am Chem Soc"},{"issue":"21","key":"11_CR182","doi-asserted-by":"publisher","first-page":"6553","DOI":"10.1021\/jm049205z","volume":"48","author":"A Wittelsberger","year":"2005","unstructured":"Wittelsberger A, Patiny L, Slaninova J et al (2005) Introduction of a cis-prolyl mimic in position 7 of the peptide hormone oxytocin does not result in antagonistic activity. J Med Chem 48(21):6553\u20136562. https:\/\/doi.org\/10.1021\/jm049205z","journal-title":"J Med Chem"},{"issue":"6","key":"11_CR183","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.ejmech.2006.12.016","volume":"42","author":"M Fragiadaki","year":"2007","unstructured":"Fragiadaki M, Magafa V, Borovickova L et al (2007) Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7. Eur J Med Chem 42(6):799\u2013806. https:\/\/doi.org\/10.1016\/j.ejmech.2006.12.016","journal-title":"Eur J Med Chem"},{"issue":"8","key":"11_CR184","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1021\/ja00164a035","volume":"112","author":"PS Hill","year":"1990","unstructured":"Hill PS, Smith DD, Slaninova J et al (1990) Bicyclization of a weak oxytocin agonist produces a highly potent oxytocin antagonist. J Am Chem Soc 112(8):3110\u20133113. https:\/\/doi.org\/10.1021\/ja00164a035","journal-title":"J Am Chem Soc"},{"issue":"9","key":"11_CR185","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1021\/jm00087a009","volume":"35","author":"DD Smith","year":"1992","unstructured":"Smith DD, Slaninova J, Hruby VJ (1992) Structure-activity studies of a novel bicyclic oxytocin antagonist. J Med Chem 35(9):1558\u20131563","journal-title":"J Med Chem"},{"issue":"29","key":"11_CR186","doi-asserted-by":"publisher","first-page":"7393","DOI":"10.1021\/ja980848b","volume":"120","author":"Subo Liao","year":"1998","unstructured":"Liao S, Shenderovich MD, Zhang Z et al (1998) Substitution of the side-chain-constrained amino acids \u03b2-methyl-2',6'-dimethyl-4'-methoxytyrosine in position 2 of a bicyclic oxytocin analogue provides unique insights into the bioactive topography of oxytocin antagonists. J Am Chem Soc 120(29):7393\u20137394. https:\/\/doi.org\/10.1021\/ja980848b","journal-title":"Journal of the American Chemical Society"},{"issue":"10","key":"11_CR187","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1021\/jm00010a020","volume":"38","author":"M Manning","year":"1995","unstructured":"Manning M, Cheng LL, Klis WA et al (1995) Effects of a D-Cys6\/L-Cys6 interchange in nonselective and selective vasopressin and oxytocin antagonists. J Med Chem 38(10):1762\u20131769","journal-title":"J Med Chem"},{"key":"11_CR188","first-page":"75","volume-title":"CRC Handbook of neurohypophyseal hormone analogs","author":"M Lebl","year":"1987","unstructured":"Lebl M (1987) Analogs with dissociated and\/or high activities. In: Jost K, Lebl M, Brtnik F (eds) CRC Handbook of neurohypophyseal hormone analogs, vol 2., pt 1. CRC Press, Boca Raton, pp 75\u2013154"},{"issue":"s1","key":"11_CR189","doi-asserted-by":"publisher","first-page":"59s","DOI":"10.1111\/j.1469-445X.2000.tb00008.x","volume":"85","author":"Bice Chini","year":"2000","unstructured":"Chini B, Fanelli F (2000) Molecular basis of ligand binding and receptor activation in the oxytocin and vasopressin receptor family. Exp Physiol 85(Spec No):59S\u201366S","journal-title":"Experimental Physiology"},{"key":"11_CR190","unstructured":"du Vigneaud V, Winestock G, Murti VVS et al (1960) Synthesis of 1-beta -mercaptopropionic acid oxytocin (deamino-oxytocin), a highly potent analog of oxytocin. J Biol Chem 235:PC 64\u2013PC 66"},{"key":"11_CR191","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0021-9258(19)83740-7","volume":"237","author":"DB Hope","year":"1962","unstructured":"Hope DB, Murti VV, Du Vigneaud V (1962) A highly potent analogue of oxytocin, desamino-oxytocin. J Biol Chem 237:1563\u20131566","journal-title":"J Biol Chem"},{"issue":"11","key":"11_CR192","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1016\/S0021-9258(18)97053-5","volume":"240","author":"BM Ferrier","year":"1965","unstructured":"Ferrier BM, Jarvis D, Du Vigneaud V (1965) Deamino-oxytocin. Its isolation by partition chromatography on Sephadex and crystallization from water, and its biological activities. J Biol Chem 240(11):4264\u20134266","journal-title":"J Biol Chem"},{"key":"11_CR193","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1039\/P19720001946","volume":"1","author":"M Walti","year":"1972","unstructured":"Walti M, Hope DB (1972) Synthesis of (1-(L-2-hydroxy-3-mercaptopropanoic acid))oxytocin, a highly potent analogue of oxytocin. J Chem Soc Perkin 1:1946\u20131950","journal-title":"J Chem Soc Perkin"},{"issue":"1","key":"11_CR194","first-page":"40","volume":"67","author":"DB Hope","year":"1974","unstructured":"Hope DB (1974) Pharmacology of hydroxy-analogues of oxytocin. Proc R Soc Med 67(1):40\u201342","journal-title":"Proc R Soc Med"},{"issue":"3","key":"11_CR195","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1021\/jm00225a007","volume":"19","author":"M Manning","year":"1976","unstructured":"Manning M, Lowbridge J, Sawyer WH et al (1976) Synthesis and some pharmacological properties of [1-(L-2-hydroxy-3-mercaptopropanoic acid), 4-threonine]oxytocin (hydroxy [4-Thr]oxytocin), a peptide with strikingly high oxytocic potency and of [1-(L-2-hydroxy-3-mercaptopropanoic acid)]oxytocin (hydroxy-oxytocin). J Med Chem 19(3):376\u2013380","journal-title":"J Med Chem"},{"issue":"20","key":"11_CR196","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1021\/bi00822a010","volume":"9","author":"M Manning","year":"1970","unstructured":"Manning M, Coy E, Sawyer WH (1970) Solid-phase synthesis of (4-threonine)-oxytocin. A more potent and specific oxytocic agent than oxytocin. Biochemistry 9(20):3925\u20133930","journal-title":"Biochemistry"},{"issue":"5259","key":"11_CR197","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/227715a0","volume":"227","author":"M Manning","year":"1970","unstructured":"Manning M, Sawyer WH (1970) 4-Threonine-oxytocin: a more active and specific oxytocic agent than oxytocin. Nature 227(5259):715\u2013716","journal-title":"Nature"},{"issue":"3","key":"11_CR198","first-page":"191","volume":"21","author":"T Barth","year":"1987","unstructured":"Barth T, Slaninova J, Lebl M et al (1987) Effect of threonine in position 4 in oxytocin and vasotocin analogs on the time course of uterotonic response. Endocrinol Exp 21(3):191\u2013197","journal-title":"Endocrinol Exp"},{"issue":"10","key":"11_CR199","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1021\/ja00504a037","volume":"101","author":"VJ Hruby","year":"1979","unstructured":"Hruby VJ, Upson DA, Yamamoto DM et al (1979) Active site studies of neurohypophyseal hormones. Comparison of oxytocin and arginine vasopressin analogs containing 2-D-tyrosine. J Am Chem Soc 101(10):2717. https:\/\/doi.org\/10.1021\/ja00504a037","journal-title":"J Am Chem Soc"},{"key":"11_CR200","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1021\/ja01514a064","volume":"81","author":"M Bodanszky","year":"1959","unstructured":"Bodanszky M, du Vigneaud V (1959) Synthesis of a biologically active analog of oxytocin, with phenylalanine replacing tyrosine. J Am Chem Soc 81:1258\u20131259","journal-title":"J Am Chem Soc"},{"key":"11_CR201","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/j.1476-5381.1959.tb00939.x","volume":"14","author":"H Konzett","year":"1959","unstructured":"Konzett H, Berde B (1959) The biological activity of a new analog of oxytocin in which the tyrosyl group is replaced by phenylalanyl. Br J Pharmacol Chemother 14:133\u2013136","journal-title":"Br J Pharmacol Chemother"},{"issue":"11","key":"11_CR202","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1135\/cccc19642648","volume":"29","author":"AL Zhuze","year":"1964","unstructured":"Zhuze AL, Jost K, Kasafirek E et al (1964) Amino acids and peptides. XLV. Analogs of oxytocin with O-ethyltyrosine, p-methylphenylalanine, and p-ethylphenylalanine replacing tyrosine. Collect Czechoslov Chem Commun 29(11):2648. https:\/\/doi.org\/10.1135\/cccc19642648","journal-title":"Collect Czechoslov Chem Commun"},{"issue":"3","key":"11_CR203","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/BF02002831","volume":"33","author":"V Pliska","year":"1977","unstructured":"Pliska V, Marbach P, Vasak J et al (1977) [2-o-Iodotyrosine]-oxytocin and [2-o-methyltyrosine]-oxytocin: basic pharmacology and comments on their potential use in binding studies. Experientia 33(3):367\u2013369","journal-title":"Experientia"},{"issue":"1","key":"11_CR204","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1135\/cccc19770195","volume":"42","author":"T Barth","year":"1977","unstructured":"Barth T (1977) Chymotryptic cleavage of deamino analogs of oxytocin. Collect Czechoslov Chem Commun 42(1):195\u2013200. https:\/\/doi.org\/10.1135\/cccc19770195","journal-title":"Collect Czechoslov Chem Commun"},{"issue":"3","key":"11_CR205","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/j.1600-0773.1997.tb00045.x","volume":"81","author":"H Vilhardt","year":"1997","unstructured":"Vilhardt H, Atke A, Barthova J et al (1997) Interaction of chymotrypsin with carbetocin ([1-deamino-1-monocarba-2-O-methyltyrosine]-oxytocin). Pharmacol Toxicol 81(3):147\u2013150","journal-title":"Pharmacol Toxicol"},{"issue":"4","key":"11_CR206","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1135\/cccc19731073","volume":"38","author":"K Jost","year":"1973","unstructured":"Jost K, Barth T, Krejci I et al (1973) Amino acids and peptides. CXIII. Carba1-oxytocin: synthesis and some of its biological properties. Collect Czechoslov Chem Commun 38(4):1073\u20131083. https:\/\/doi.org\/10.1135\/cccc19731073","journal-title":"Collect Czechoslov Chem Commun"},{"issue":"5","key":"11_CR207","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1002\/hlca.19740570502","volume":"57","author":"O Keller","year":"1974","unstructured":"Keller O, Rudinger J (1974) Synthesis of (1,6-alpha,alpha'-diaminosuberic acid)oxytocin ('dicarba-oxytocin'). Helv Chim Acta 57(5):1253\u20131259. https:\/\/doi.org\/10.1002\/hlca.19740570502","journal-title":"Helv Chim Acta"},{"issue":"24","key":"11_CR208","doi-asserted-by":"publisher","first-page":"8585","DOI":"10.1021\/jm100989w","volume":"53","author":"M Muttenthaler","year":"2010","unstructured":"Muttenthaler M, Andersson A, de Araujo AD et al (2010) Modulating oxytocin activity and plasma stability by disulfide bond engineering. J Med Chem 53(24):8585\u20138596. https:\/\/doi.org\/10.1021\/jm100989w","journal-title":"J Med Chem"},{"key":"11_CR209","unstructured":"Pliska V, Jutz G, Beck S (1985) Molecular sites of oxytocin inactivation in the rat uterus: in vitro investigation with enzyme probes using oil-immersion technique. In: Deber CM, Hruby VJ, Kopple KD (eds) Peptides: structure and function. Proceedings of the ninth American Peptide Symposium, Toronto, Canada. Pierce Chemical Company, pp 603\u2013606"},{"issue":"10","key":"11_CR210","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1007\/BF02150299","volume":"20","author":"J Rudinger","year":"1964","unstructured":"Rudinger J, Jost K (1964) A biologically active analogue of oxytocin not containing a disulfide group. Experientia 20(10):570\u2013571","journal-title":"Experientia"},{"issue":"2","key":"11_CR211","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/0014-2999(73)90070-8","volume":"24","author":"T Barth","year":"1973","unstructured":"Barth T, Krejci I, Kupkova B et al (1973) Pharmacology of cyclic analogues of deamino-oxytocin not containing a disulphide bond (carba analogues). Eur J Pharmacol 24(2):183\u2013188","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"11_CR212","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/0014-2999(74)90095-8","volume":"25","author":"T Barth","year":"1974","unstructured":"Barth T, Krejci I, Vaneckova J et al (1974) Prolonged action of deamino-carba analogues of oxytocin on the rat uterus in vivo. Eur J Pharmacol 25(1):67\u201370","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"11_CR213","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1135\/cccc19741290","volume":"39","author":"I Fric","year":"1974","unstructured":"Fric I, Kodicek M, Prochaszka Z et al (1974) Amino acids and peptides. CXXI. Synthesis and circular dichroism of some deamino-1-carbaoxytocin analogs with modifications of the amino acid residue at position 2. Collect Czechoslov Chem Commun 39(5):1290\u20131302. https:\/\/doi.org\/10.1135\/cccc19741290","journal-title":"Collect Czechoslov Chem Commun"},{"issue":"2\u20133","key":"11_CR214","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0014-2999(98)00513-5","volume":"355","author":"T Engstrom","year":"1998","unstructured":"Engstrom T, Barth T, Melin P et al (1998) Oxytocin receptor binding and uterotonic activity of carbetocin and its metabolites following enzymatic degradation. Eur J Pharmacol 355(2\u20133):203\u2013210","journal-title":"Eur J Pharmacol"},{"issue":"11","key":"11_CR215","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.1135\/cccc19803045","volume":"45","author":"T Barth","year":"1980","unstructured":"Barth T, Slaninova J, Lebl M et al (1980) Biological activities and protracted action of carba-analogs of deamino-oxytocin with O-methyltyrosine in position 2. Collect Czechoslov Chem Commun 45(11):3045\u20133050. https:\/\/doi.org\/10.1135\/cccc19803045","journal-title":"Collect Czechoslov Chem Commun"},{"issue":"1","key":"11_CR216","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/clpt.1992.103","volume":"52","author":"DJ Hunter","year":"1992","unstructured":"Hunter DJ, Schulz P, Wassenaar W (1992) Effect of carbetocin, a long-acting oxytocin analog on the postpartum uterus. Clin Pharmacol Ther 52(1):60\u201367","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"11_CR217","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/OGX.0b013e3181932e5b","volume":"64","author":"NC Peters","year":"2009","unstructured":"Peters NC, Duvekot JJ (2009) Carbetocin for the prevention of postpartum hemorrhage: a systematic review. Obstet Gynecol Surv 64(2):129\u2013135. https:\/\/doi.org\/10.1097\/OGX.0b013e3181932e5b","journal-title":"Obstet Gynecol Surv"},{"issue":"1","key":"11_CR218","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ejogrb.2009.06.018","volume":"147","author":"W Rath","year":"2009","unstructured":"Rath W (2009) Prevention of postpartum haemorrhage with the oxytocin analogue carbetocin. Eur J Obstet Gynecol Reprod Biol 147(1):15\u201320. https:\/\/doi.org\/10.1016\/j.ejogrb.2009.06.018","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"8","key":"11_CR219","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1111\/j.1471-0528.2010.02585.x","volume":"117","author":"G Attilakos","year":"2010","unstructured":"Attilakos G, Psaroudakis D, Ash J et al (2010) Carbetocin versus oxytocin for the prevention of postpartum haemorrhage following caesarean section: the results of a double-blind randomised trial. BJOG 117(8):929\u2013936. https:\/\/doi.org\/10.1111\/j.1471-0528.2010.02585.x","journal-title":"BJOG"},{"key":"11_CR220","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ijoa.2016.10.003","volume":"28","author":"LS Meshykhi","year":"2016","unstructured":"Meshykhi LS, Nel MR, Lucas DN (2016) The role of carbetocin in the prevention and management of postpartum haemorrhage. Int J Obstet Anesth 28:61\u201369. https:\/\/doi.org\/10.1016\/j.ijoa.2016.10.003","journal-title":"Int J Obstet Anesth"},{"key":"11_CR221","unstructured":"Danglas P, Reidy M, Korner P et al (2016) Method of treating Prader-Willi syndrome using oxytocin receptor agonists. WO2016044131"},{"key":"11_CR222","unstructured":"Leonard AK, Sestak JO, Costantino HR et al (2012) Intranasal carbetocin formulations and methods for the treatment of autism. US20120172304"},{"issue":"1","key":"11_CR223","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1515\/bchm2.1964.339.1.222","volume":"339","author":"W Frank","year":"1964","unstructured":"Frank W (1964) Syntheses of selenium-containing peptides. 3. Diseleno-oxytocin. Hoppe Seylers Z Physiol Chem 339(1):222\u2013229","journal-title":"Hoppe Seylers Z Physiol Chem"},{"issue":"15","key":"11_CR224","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1021\/ja00991a037","volume":"89","author":"R Walter","year":"1967","unstructured":"Walter R, Chan W-Y (1967) Syntheses and pharmacological properties of selenium isologs of oxytocin and deaminooxytocin. J Am Chem Soc 89(15):3892\u20133898. https:\/\/doi.org\/10.1021\/ja00991a037","journal-title":"J Am Chem Soc"},{"issue":"18","key":"11_CR225","doi-asserted-by":"publisher","first-page":"4192","DOI":"10.1021\/ja01096a036","volume":"87","author":"R Walter","year":"1965","unstructured":"Walter R, du Vigneaud V (1965) 6-Hemi-L-selenocystine-oxytocin and 1-deamino-6-hemi-L-selenocystine-oxytocin, highly potent isologs of oxytocin and 1-deaminooxytocin. J Am Chem Soc 87(18):4192\u20134193. https:\/\/doi.org\/10.1021\/ja01096a036","journal-title":"J Am Chem Soc"},{"issue":"6","key":"11_CR226","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1021\/ja00958a053","volume":"88","author":"R Walter","year":"1966","unstructured":"Walter R, du Vigneaud V (1966) 1-Deamino-1,6-L-selenocystineoxytocin; a highly potent isolog of 1-deaminooxytocin. J Am Chem Soc 88(6):1331\u20131332. https:\/\/doi.org\/10.1021\/ja00958a053","journal-title":"J Am Chem Soc"},{"key":"11_CR227","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4165","volume":"5","author":"AD Araujo de","year":"2014","unstructured":"de Araujo AD, Mobli M, Castro J et al (2014) Selenoether oxytocin analogues have analgesic properties in a mouse model of chronic abdominal pain. Nat Commun 5:3165. https:\/\/doi.org\/10.1038\/ncomms4165","journal-title":"Nat Commun"},{"issue":"508","key":"11_CR228","doi-asserted-by":"publisher","first-page":"eaan3398","DOI":"10.1126\/scisignal.aan3398","volume":"10","author":"Markus Muttenthaler","year":"2017","unstructured":"Muttenthaler M, Andersson A, Vetter I et al (2017) Subtle modifications to oxytocin produce ligands that retain potency and improved selectivity across species. Sci Signal 10(508). https:\/\/doi.org\/10.1126\/scisignal.aan3398","journal-title":"Science Signaling"},{"issue":"1","key":"11_CR229","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1021\/jm00319a014","volume":"9","author":"BM Ferrier","year":"1966","unstructured":"Ferrier BM, Vd V (1966) 9-Deamidooxytocin, an analog of the hormone containing a glycine residue in place of the glycinamide residue. J Med Chem 9(1):55\u201357. https:\/\/doi.org\/10.1021\/jm00319a014","journal-title":"J Med Chem"},{"issue":"1","key":"11_CR230","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1021\/jm00199a023","volume":"21","author":"CW Smith","year":"1978","unstructured":"Smith CW, Walter R, Moore S et al (1978) Replacement of the disulfide bond in oxytocin by an amide group. Synthesis and some biological properties of (cyclo-(1-L-aspartic acid,6-L-alpha,beta-diaminopropionic acid))oxytocin. J Med Chem 21(1):117\u2013120","journal-title":"J Med Chem"},{"key":"11_CR231","unstructured":"Bissantz C, Bleicher K, Grundschober C (2014) Peptides as oxytocin receptor agonists and their use in treatment of mental and behavioral disorders. WO2014095773"},{"key":"11_CR232","unstructured":"Bissantz C, Bleicher K, Grundschober C (2015) Peptides as oxytocin receptor agonists and their use in treatment of mental and behavioral disorders. WO2015185467"},{"key":"11_CR233","unstructured":"Bleicher K, Cueni A, Puentener K et al (2016) Preparation of oxytocin analogs as oxytocin receptor agonists and their use in treatment of neurological disorders. WO2016020349A1"},{"issue":"11","key":"11_CR234","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1016\/j.bmcl.2017.04.030","volume":"27","author":"Y Adachi","year":"2017","unstructured":"Adachi Y, Sakimura K, Shimizu Y et al (2017) Potent and selective oxytocin receptor agonists without disulfide bridges. Bioorg Med Chem Lett 27(11):2331\u20132335. https:\/\/doi.org\/10.1016\/j.bmcl.2017.04.030","journal-title":"Bioorg Med Chem Lett"},{"key":"11_CR235","unstructured":"Bissantz C, Bleicher K, Chakraborty K et al (2016) Peptides as oxytocin receptor agonists and their use in treatment of mental and behavioral disorders. WO2015185584"},{"issue":"6","key":"11_CR236","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1135\/cccc19781538","volume":"43","author":"M Lebl","year":"1978","unstructured":"Lebl M, Barth T, Jost K (1978) Amino acids and peptides. Part CIL. Synthesis, reduction, and pharmacological properties of the sulfoxides of some carba-analogs of oxytocin. Collect Czechoslov Chem Commun 43(6):1538. https:\/\/doi.org\/10.1135\/cccc19781538","journal-title":"Collect Czechoslov Chem Commun"},{"issue":"2","key":"11_CR237","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1021\/jm00224a010","volume":"19","author":"CW Smith","year":"1976","unstructured":"Smith CW, Ferger MF (1976) Synthesis and some pharmacological properties of five analogs of oxytocin having L-homocysteine in position 6. J Med Chem 19(2):250\u2013254","journal-title":"J Med Chem"},{"issue":"6","key":"11_CR238","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1021\/jm9607156","volume":"40","author":"L Chen","year":"1997","unstructured":"Chen L, Zoulikova I, Slaninova J et al (1997) Synthesis and pharmacology of novel analogs of oxytocin and deaminooxytocin: directed methods for the construction of disulfide and trisulfide bridges in peptides. J Med Chem 40(6):864\u2013876","journal-title":"J Med Chem"},{"key":"11_CR239","unstructured":"Bodanszky M, Bath RJ (1968) Hindered amines in peptide synthesis. Synthesis of 7-glycine-oxytocin. Chem Commun (13):766\u2013767"},{"issue":"8","key":"11_CR240","first-page":"1684","volume":"38","author":"ZD Bespalova","year":"1968","unstructured":"Bespalova ZD, Martynov VF, Titov MI (1968) New analogs of oxytocin, 7-glycineoxytocin and 7-D-leucineoxytocin. Zh Obshch Khim 38(8):1684\u20131687","journal-title":"Zh Obshch Khim"},{"issue":"6","key":"11_CR241","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1021\/jm00228a017","volume":"19","author":"R Walter","year":"1976","unstructured":"Walter R, Smith CW, Roy J et al (1976) Oxytocin analogues with combined high smooth muscle and negligible antidiuretic activities. Investigation of position 7 in neurohypophyseal hormones. J Med Chem 19(6):822\u2013825","journal-title":"J Med Chem"},{"issue":"5","key":"11_CR242","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1073\/pnas.71.5.1901","volume":"71","author":"R Walter","year":"1974","unstructured":"Walter R, Yamanaka T, Sakakibara S (1974) A neurohypophyseal hormone analog with selective oxytocin-like activities and resistance to enzymatic inactivation: an approach to the design of peptide drugs. Proc Natl Acad Sci U S A 71(5):1901\u20131905","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"11_CR243","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1021\/jm00366a028","volume":"26","author":"Z Grzonka","year":"1983","unstructured":"Grzonka Z, Lammek B, Gazis D et al (1983) Synthesis and some pharmacological properties of [4-threonine,7-sarcosine]oxytocin, a peptide with high oxytocic potency, and of [4-threonine,7-N-methylalanine]oxytocin. J Med Chem 26(12):1786\u20131787","journal-title":"J Med Chem"},{"issue":"4","key":"11_CR244","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1021\/jm00358a018","volume":"26","author":"Z Grzonka","year":"1983","unstructured":"Grzonka Z, Lammek B, Kasprzykowski F et al (1983) Synthesis and some pharmacological properties of oxytocin and vasopressin analogues with sarcosine or N-methyl-L-alanine in position 7. J Med Chem 26(4):555\u2013559","journal-title":"J Med Chem"},{"issue":"1","key":"11_CR245","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1021\/jm00211a025","volume":"20","author":"J Lowbridge","year":"1977","unstructured":"Lowbridge J, Manning M, Haldar J et al (1977) Synthesis and some pharmacological properties of [4-threonine, 7-glycine]oxytocin, [1-(L-2-hydroxy-3-mercaptopropanoic acid), 4-threonine, 7-glycine]oxytocin (hydroxy[Thr4, Gly7]oxytocin), and [7-Glycine]oxytocin, peptides with high oxytocic-antidiuretic selectivity. J Med Chem 20(1):120\u2013123","journal-title":"J Med Chem"},{"key":"11_CR246","doi-asserted-by":"crossref","unstructured":"Tence M, Guillon G, Bottari S et al (1990) Labelling of vasopressin and oxytocin receptors from the human uterus. Eur J Pharmacol 191(3):427\u2013436. https:\/\/doi.org\/0014-2999(90)94177-Y","DOI":"10.1016\/0014-2999(90)94177-Y"},{"issue":"3","key":"11_CR247","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/0306-4522(94)90476-6","volume":"62","author":"R Mihai","year":"1994","unstructured":"Mihai R, Coculescu M, Wakerley JB et al (1994) The effects of [Arg8]vasopressin and [Arg8]vasotocin on the firing rate of suprachiasmatic neurons in vitro. Neuroscience 62(3):783\u2013792","journal-title":"Neuroscience"},{"issue":"4","key":"11_CR248","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/j.0953-8194.2004.01163.x","volume":"16","author":"G. Guillon","year":"2004","unstructured":"Guillon G, Derick S, Pena A et al (2004) The discovery of novel vasopressin V1b receptor ligands for pharmacological, functional and structural investigations. J Neuroendocrinol 16(4):356\u2013361. https:\/\/doi.org\/10.1111\/j.0953-8194.2004.01163.x","journal-title":"Journal of Neuroendocrinology"},{"issue":"13","key":"11_CR249","doi-asserted-by":"publisher","first-page":"4388","DOI":"10.1021\/jm200278m","volume":"54","author":"K Wisniewski","year":"2011","unstructured":"Wisniewski K, Galyean R, Tariga H et al (2011) New, potent, selective, and short-acting peptidic V1a receptor agonists. J Med Chem 54(13):4388\u20134398. https:\/\/doi.org\/10.1021\/jm200278m","journal-title":"J Med Chem"},{"issue":"7","key":"11_CR250","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1021\/jm00229a003","volume":"19","author":"JD Rosamond","year":"1976","unstructured":"Rosamond JD, Ferger MF (1976) Synthesis and some pharmacological properties of oxytocin analogues having L-thiazolidine-4-carboxylic acid in position 7. J Med Chem 19(7):873\u2013876","journal-title":"J Med Chem"},{"issue":"4","key":"11_CR251","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/j.1399-3011.1985.tb02188.x","volume":"25","author":"Z Grzonka","year":"1985","unstructured":"Grzonka Z, Mishra PK, Bothner-By AA (1985) Conformational preferences and binding to neurophysins of oxytocin analogs with sarcosine or N-methylalanine in position 7. Int J Pept Protein Res 25(4):375\u2013381","journal-title":"Int J Pept Protein Res"},{"issue":"1","key":"11_CR252","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1677\/joe.0.0490151","volume":"49","author":"WH Sawyer","year":"1971","unstructured":"Sawyer WH, Manning M (1971) 4-Threonine analogues of neurohypophysial hormones with selectively enhanced oxytocin-like activities. J Endocrinol 49(1):151\u2013165","journal-title":"J Endocrinol"},{"issue":"12","key":"11_CR253","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1007\/BF01185751","volume":"56","author":"M Rimpler","year":"1969","unstructured":"Rimpler M, Schoeberl A (1969) Synthesis of nonapeptide with oxytocin activity. Naturwissenschaften 56(12):638","journal-title":"Naturwissenschaften"},{"key":"11_CR254","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/jlac.19717450103","volume":"745","author":"M Rimpler","year":"1971","unstructured":"Rimpler M (1971) [1-Deamino]lysinevasotocin, a disulfide polypeptide exhibiting oxytocin activity. Justus Liebigs Ann Chem 745:8\u201319","journal-title":"Justus Liebigs Ann Chem"},{"issue":"7","key":"11_CR255","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/BF01924209","volume":"30","author":"D Surovec","year":"1974","unstructured":"Surovec D, Hoffman PL, Walter R (1974) Comparison of some biological activities of arginine vasotocin and synthetic analogs. Experientia 30(7):823\u2013824","journal-title":"Experientia"},{"issue":"5","key":"11_CR256","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/sj.bjc.6601189","volume":"89","author":"B Chini","year":"2003","unstructured":"Chini B, Chinol M, Cassoni P et al (2003) Improved radiotracing of oxytocin receptor-expressing tumours using the new [111In]-DOTA-Lys8-deamino-vasotocin analogue. Br J Cancer 89(5):930\u2013936. https:\/\/doi.org\/10.1038\/sj.bjc.6601189","journal-title":"Br J Cancer"},{"issue":"15","key":"11_CR257","doi-asserted-by":"publisher","first-page":"7152","DOI":"10.1021\/acs.jmedchem.6b00564","volume":"59","author":"M Busnelli","year":"2016","unstructured":"Busnelli M, Kleinau G, Muttenthaler M et al (2016) Design and characterization of superpotent bivalent ligands targeting oxytocin receptor dimers via a channel-like structure. J Med Chem 59(15):7152\u20137166. https:\/\/doi.org\/10.1021\/acs.jmedchem.6b00564","journal-title":"J Med Chem"},{"issue":"8","key":"11_CR258","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1135\/cccc19892261","volume":"54","author":"J Hlavacek","year":"1989","unstructured":"Hlavacek J, Fric I (1989) Amino acids and peptides. Part CCXIII. The effect of non-coded amino acids on the degradation of oxytocin analogs with \u03b1-chymotrypsin. Collect Czechoslov Chem Commun 54(8):2261. https:\/\/doi.org\/10.1135\/cccc19892261","journal-title":"Collect Czechoslov Chem Commun"},{"issue":"16","key":"11_CR259","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.1016\/j.bmc.2016.05.062","volume":"24","author":"S Sciabola","year":"2016","unstructured":"Sciabola S, Goetz GH, Bai G et al (2016) Systematic N-methylation of oxytocin: Impact on pharmacology and intramolecular hydrogen bonding network. Bioorg Med Chem 24(16):3513\u20133520. https:\/\/doi.org\/10.1016\/j.bmc.2016.05.062","journal-title":"Bioorg Med Chem"},{"issue":"Suppl 1","key":"11_CR260","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1046\/j.1365-4362.36.s1.2.x","volume":"36","author":"MG Choc","year":"1997","unstructured":"Choc MG (1997) Bioavailability and pharmacokinetics of cyclosporine formulations: Neoral vs Sandimmune. Int J Dermatol 36(Suppl 1):1\u20136","journal-title":"Int J Dermatol"},{"issue":"7","key":"11_CR261","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1021\/jm401859b","volume":"57","author":"GH Goetz","year":"2014","unstructured":"Goetz GH, Farrell W, Shalaeva M et al (2014) High throughput method for the indirect detection of intramolecular hydrogen bonding. J Med Chem 57(7):2920\u20132929. https:\/\/doi.org\/10.1021\/jm401859b","journal-title":"J Med Chem"},{"issue":"5","key":"11_CR262","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1073\/pnas.68.5.956","volume":"68","author":"DW Urry","year":"1971","unstructured":"Urry DW, Walter R (1971) Proposed conformation of oxytocin in solution. Proc Natl Acad Sci U S A 68(5):956\u2013958","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"11_CR263","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/mrc.2557","volume":"48","author":"A Ohno","year":"2010","unstructured":"Ohno A, Kawasaki N, Fukuhara K et al (2010) Complete NMR analysis of oxytocin in phosphate buffer. Magn Reson Chem 48(2):168\u2013172. https:\/\/doi.org\/10.1002\/mrc.2557","journal-title":"Magn Reson Chem"},{"issue":"4","key":"11_CR264","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1358\/dof.2006.031.04.980655","volume":"31","author":"DM Ashworth","year":"2006","unstructured":"Ashworth DM, Batt AR, Baxter AJ et al (2006) Nonpeptide oxytocin agonists. Drugs Future 31(4):345\u2013353","journal-title":"Drugs Future"},{"issue":"3","key":"11_CR265","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.bmcl.2017.12.027","volume":"28","author":"N Kablaoui","year":"2018","unstructured":"Kablaoui N, Vanase-Frawley M, Sciabola S (2018) Hybrid peptide-small molecule oxytocin analogs are potent and selective agonists of the oxytocin receptor. Bioorg Med Chem Lett 28(3):415\u2013419. https:\/\/doi.org\/10.1016\/j.bmcl.2017.12.027","journal-title":"Bioorg Med Chem Lett"},{"issue":"3","key":"11_CR266","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1210\/jcem.87.3.8537","volume":"87","author":"C Breton","year":"2002","unstructured":"Breton C, Haenggeli C, Barberis C et al (2002) Presence of functional oxytocin receptors in cultured human myoblasts. J Clin Endocrinol Metab 87(3):1415\u20131418. https:\/\/doi.org\/10.1210\/jcem.87.3.8537","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Methods in Molecular Biology","Cyclic Peptide Design"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4939-9504-2_11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T22:46:48Z","timestamp":1694904408000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4939-9504-2_11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9781493995035","9781493995042"],"references-count":266,"URL":"https:\/\/doi.org\/10.1007\/978-1-4939-9504-2_11","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]},"assertion":[{"value":"28 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}